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Abstract 
Depression increases the risk of Alzheimer disease (AD); however, some of this risk might 
be associated with the type of antidepressant drug used to treat the depression. Indeed, a significant 
risk has been associated with selective serotonin reuptake inhibitors (SSRIs). SSRIs increase 
synaptic serotonin levels by inhibiting the serotonin transporter (SERT). It has been reported that 
SERT can transport molecules other than serotonin. One such molecule is the 14 kDa protein α-
synuclein (a protein which accumulates in the Parkinson disease brain). Therefore, it is possible 
that the AD-related, 4 kDa beta-amyloid (Aβ), may also be transported by SERT, and the inhibition 
of SERT by SSRIs could inadvertently result in the intracellular accumulation of Aβ and, 
ultimately, cell death and plaque formation (a hallmark of AD pathology).  
Caenorhabditis elegans (C. elegans) and mammalian cell culture were used to study the 
effects of selected SSRIs, i.e. Fluoxetine and its major metabolite, nor-Fluoxetine, on the 
accumulation of Aβ. The expression of Aβ1-42 in our transgenic C. elegans strain is under the 
control of the muscle promoter and is therefore specific to the muscle. Any accumulation causes a 
loss of motility/paralysis phenotype. Both Fluoxetine and nor-Fluoxetine exacerbated paralysis in 
C. elegans expressing Aβ1-42. To confirm a role for the worm analogue of SERT, MOD-5, in this 
effect, a worm was generated that carried the Aβ1-42 peptide on a truncated MOD-5 background. 
Paralysis was also exacerbated in this cross-bred worm strain (versus the parental strain that just 
expressed the Aβ1-42 peptide), even in the absence of SSRI treatment.  The degree of paralysis in 
a worm that carried the Aβ1-42 peptide on a TPH-1 (tryptophan hydroxylase) null background (thus, 
inhibiting the synthesis of serotonin) was similar to that in the parental strain that just expressed 
the Aβ1-42 peptide. Thus, any paralysis in this worm model was not dependent on any change in in 
serotonin availability. The experiments based on mammalian cell cultures, although showing 
promise, were not as conclusive and need further optimization.  
Given the increased practice of prescribing SSRIs for off-label purposes, a significant 
number of individuals could be unknowingly put at risk for AD through a mechanism based on 
inhibition of SERT-mediated transport and intracellular accumulation of Aβ peptides. These 
observations will hopefully lead to a change in prescription practices. 
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1 Introduction 
1.1 Alzheimer disease 
Alzheimer disease (AD) is a neurodegenerative disorder that is responsible for almost 70% 
of dementia cases1. AD primarily affects thought, language, and memory; however, as this disease 
progresses, some motor dysfunction can also occur. Typical cognitive symptoms are mild 
forgetfulness that can grow to be more severe over time; confusion with names and simple math 
problems; forgetting everyday tasks; difficulties speaking and understanding speech; problems 
with reading and writing; behavioural changes; and anxious, aggressive, or aimless behaviour2. 
The impairment seen in people with AD is the result of synaptic damage, degeneration of axons, 
and atrophy within many regions of the brain including the hippocampus, entorhinal cortex, 
ventricles, amygdala, putamen, caudate, thalamus, and much of the cortex3.  
Although the indicators for diagnosing AD post-mortem are distinct, this is the only time 
that a definite diagnosis can be determined. However, in recent years, new technologies and 
research have allowed for other markers, such as cerebrospinal fluid (CSF) levels of the 
cytoskeletal protein tau and the hydrophobic, 4 kDa peptide beta-amyloid (Aβ), used to detect AD 
and its development4. Many genes are thought to be implicated, but very few have been confirmed 
to have a direct influence on the development of this disorder. An allele of apolipoprotein E (ApoE 
ε4)5–7, mutations within presenilin 1 and 2 (PSEN-1 and PSEN-2), and the amyloid precursor 
protein (APP)8,9 can influence the risk for, and development of, AD by regulating the generation 
and/or clearance of the Aβ-like peptides. When dysfunctional, Aβ is prevented from being cleared 
from the brain (i.e. APOE ε4) or converted into hydrophobic variants (i.e. APP, PSEN1, PSEN2), 
all of which aid in the formation of plaques1. In addition to these four genes, the sortilin-related 
receptor (SORL1) also influences the risk for AD as it is involved in trafficking APP 
intracellularly10. The five genes discussed are summarized in Table 1. Outside of these, any other 
genes studied have not produced reliable results or shown a consistent relationship with the 
development of AD10. 
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Table 1.1: Summary of genes associated with AD. 
Gene Protein Animal 
System 
Impact on Aβ 
ApoE ε45,6 Apolipoprotein E 
ε4 
Human5 ApoE normally binds Aβ; however, the 
APOE ε4 variant does not, resulting in 
less clearance of Aβ from the brain and 
accumulation of plaques5 
PSEN-111 
 
Presenilin-1 Human and 
C. elegans11 
 
PS-1 is the catalytic core of γ-
secretase12, an enzyme required for 
cleavage of APP. Mutations in PSEN-1 
cause an increased production of longer 
Aβ variants13. 
PSEN-214,15 Presenilin-2 Human14 
 
PS-2 is another component of the 
enzyme used to cleave APP. Mutations 
in this gene have been found to be 
associated with an increase in Aβ16. 
APP8 
 
Amyloid precursor 
protein 
Human8 
 
Mutations in this gene alter processing, 
causing an increase in Aβ17. 
SORL118 
 
Sortilin-related 
receptor1 
Human19 
 
This protein is involved in the sorting of 
APP and determines whether APP is 
directed through a recycling pathway or 
a breakdown pathway, producing Aβ19. 
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Brain tissues from AD patients present two molecular hallmarks, neurofibrillary tangles 
(NFTs) and amyloid plaques, that appear to contribute to the disease symptoms2. NFTs are 
composed of 10 nm diameter fibrils and consist primarily of Tau protein, a microtubule-associated 
protein that is misfolded when hyperphosphorylated20. The NFTs have a helical shape when fibrils 
pair up21. Neuronal degeneration caused by NFTs typically begins in the medial temporal lobe in 
the allocortex and continues to the multimodal association area, proceeding through six stages 
described as Braak stages22. The transentorhinal region has NFT accumulation in Stage I, followed 
by an affected entorhinal cortex proper and CA1 of the hippocampus in Stage II. By Stage III these 
filaments are found in the limbic structures, which progress into the amygdala, thalamus, and 
claustrum in the subsequent stage. In Stage V, NFTs are present in multimodal regions, and by 
Stage VI, the primary sensory, motor, and visual areas have NFT accumulation22.  
Amyloid plaques are also very common within the brains of people with AD, but it has 
been shown that people can still develop dementia without having significant amyloid deposition23, 
while there is strong evidence of significant amyloid plaque in certain cognitively intact elderly 
individuals24. Therefore, the role of the ‘plaque’ remains contentious; however, soluble Aβ 
peptides are known to exert toxic effects on cells25. APP can be metabolized via two distinct 
pathways. One pathway produces Aβ peptides through cleavage by β-secretase and γ-secretase26 
and the other is produced by α-secretase and γ-secretase. α-Secretase cleaves at a site within the 
Aβ peptide sequence and impedes the generation of the intact peptide, thus supporting a 
neuroprotective, anti-AD role for this enzyme. The specific physiological roles of the full APP 
peptide are not well known27; however, it has been reported that APP is involved in 
embryogenesis28, neurite outgrowth29, neuronal migration30, and regulating neural progenitor cell 
proliferation in adult brains31, with the conclusion that the physiological role of APP within the 
brain is one of neuroprotection27. Along with post-translational modifications, processing of APP 
can therefore lead to different Aβ isoforms and APP metabolites.  
The dominant isoform of amyloid within plaques is Aβ1-42. Total Aβ content does not 
increase in AD, but instead alterations in β-secretase activity will favor the generation of Aβ1-4232. 
This is a very hydrophobic peptide with a higher rate of fibrillization due to two additional 
residues, both hydrophobic, on the C-terminus (i.e. Ile and Ala), resulting in a much greater 
likelihood of its aggregation26 intracellularly after being produced by the secretory pathway within 
the endoplasmic reticulum33. As mentioned above, there are many variants of amyloid that are 
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found within the brain due to the different pathways involved in APP cleavage. These other 
isoforms are also present within the plaques or, if they are soluble, can remain diffuse. Both soluble 
and insoluble Aβ may contribute to the total amyloid burden within the brain, but there are 
contradictory data about the actual physiological role of Aβ34,35. However, a loss of synaptic 
plasticity is highly associated with Aβ1-42 deposition within the cells compared to Aβ being 
released extracellularly25. Aβ accumulation within brain regions is more variable than the 
progression of tau tangles with the multimodal association area often showing the highest level of 
aggregation. After the associate cortex, the entorhinal cortex, hippocampus, basal ganglia, 
brainstem nuclei, and cerebellum are affected by the accumulation of Aβ, but to a lesser extent34, 
in addition to the primary sensory, visual, and motor areas35. Braak and Braak described the 
progression of Aβ accumulation by separating the advancement into three stages22. The first, Stage 
A, begins with accumulation within the basal area of the frontal, temporal, and occipital lobes. The 
accumulation progresses into the multimodal association regions and hippocampus in Stage B. 
Finally, Stage C is characterized by plaques in all areas of the primary cortex. During this final 
stage, plaques can be present within the cerebellum, striatum, hypothalamus, subthalamic nucleus, 
thalamus, and red nucleus, as well22.  
Typically, once the patient is given a clinical diagnosis of AD, their NFT and Aβ 
aggregation has reached Braak Stages V/VI and Stage C of NFTs and Aβ, respectively22. As NFTs 
and Aβ accumulate within different areas of the brain, their presence, especially that of NFT, is 
associated with degeneration of those specific regions. The progression of the accumulation of 
toxic proteins is responsible for the cognitive symptoms displayed by individuals with AD. As the 
disease progresses, any areas affected by degeneration enlarges; the functions and behaviours 
controlled by these brain regions are also affected, producing neurological symptoms. Early 
neurofibrillary degeneration results in isolation of the medial temporal lobe from the subcortical 
nuclei and multimodal association area, causing the characteristic symptom of AD (i.e. short-term 
memory) by reducing the stimuli received from these regions36. Further cognitive decline occurs 
as accumulation moves into the cortical areas. This degeneration includes damage to the prefrontal 
cortex resulting in high-order executive dysfunction; apraxia caused by degeneration of the parietal 
cortex, visuospatial navigation and visuoperceptive mistakes due to deficits within the 
occipitoparietal cortex, and deterioration of the anterior temporal cortex causing semantic memory 
loss, finally resulting in severe dementia22,36. NFTs are also positively correlated with the presence 
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of microgliosis and astrocytosis, both of which are signs of substantial neuronal loss, and increased 
atrophy3,37.  
The distribution and extent of the plaque and tangle aggregation are also informative, in 
addition to obvious atrophy, in determining the pathology of AD at autopsy; however, there have 
been advances in diagnostic tools allowing for more accurate AD diagnosis earlier in the disease 
process38. Cerebrospinal fluid (CSF), which circulates throughout the brain and helps to remove 
‘waste’, can be an effective reflection of pathological changes in the brain. Testing CSF for some 
indication as to the risk for AD developing later in life centers on levels of Aβ, total tau, and 
hyperphosphorylated tau38. However, little differences are seen between mild cognitive 
impairment and the onset of AD4, thus CSF levels of these proteins are not yet reliable markers for 
assessing the early stages of disease progression. In addition, amyloid levels can be viewed using 
positron emission tomography (PET) imaging, but this method also has its limitations39. In 
individuals with mild to moderate dementia, 10-35% of the cases present with negative scans when 
using PET to look for amyloid deposition23. Although these biomarkers do allow for a more 
confident diagnosis when combined with clinical measures, especially in the early stages40, the 
results above suggest that the diagnostic tests prior to autopsy are not completely accurate in their 
determination of AD and that reliable pathology markers have still not been found. 
There is also research that suggests that AD may be transmissible41,42, as with other prion 
diseases. The prion paradigm describes a commonality between a number of neurodegenerative 
disorders where aggregation of a toxic protein is found43. Some evidence has shown that 
inoculation of a non-primate brain with AD brain homogenates can result in the formation of Aβ 
plaques42; therefore, Aβ may be the prion-like peptide resulting in the neurodegeneration seen 
within AD. Prion diseases are associated with neuronal loss, astrocytosis, and the accumulation of 
misfolded prion protein44,45, all of which are very similar to pathologies consistent with AD. If Aβ 
is able to be transmitted throughout the brain furthering deterioration, this would have an impact 
on how we should be pharmacologically treating AD. 
Although a specific ‘cause’ that might explain what triggers an AD-like pathology is not 
presently known, there are several factors associated with the development of AD. Lifestyle, 
physical, and psychological aspects all appear to play a role in how vulnerable a person is to this 
neurodegenerative disorder. Diet plays a large role in most physical health concerns and 
treatments, and as such it is not surprising that a balanced diet consisting of unprocessed, whole 
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foods helps to reduce the risk of AD10,46,47. As well, consistent physical activity appears to reduce 
the risk of AD for many reasons. Physical activity can increase glucose utilization, oxygen 
extraction, cerebral blood flow, and capillary density; all of which have been shown to promote 
better cognition and decrease amyloid plaque formation in rodents48. Both increased blood flow 
and capillary density would promote clearance of the amyloid peptide and preclude the formation 
of plaques; thus, physical activity appears to indirectly play a role. Cognitive activities are also 
associated with reduced risk for AD in both younger and older groups of people10,49. In contrast, 
some pre-existing disorders and diseases may increase an individual’s vulnerability to AD49. 
Cerebrovascular disease including hemorrhagic infarcts, ischemic cortical infarcts, and 
vasculopathies can lead to direct damage of brain regions important in memory function and may 
increase accumulation of Aβ10. Type-2 diabetes (T2D) also doubles the risk of AD50,51, likely due 
to both cerebrovascular and non-cerebrovascular mechanisms involved with T2D52. As well, 
traumatic brain injury (TBI) increased a person’s risk for AD when compared to individuals with 
no history of TBI53. Metabolic syndrome has also been shown to have a positive association with 
cognitive dysfunction54. Consistent with metabolic syndrome, high body mass index (BMI) and 
obesity are also thought to make an individual more vulnerable to AD49. The psychological side 
of health can also influence the development of AD; individuals facing consistent stress were 
found to have an increased risk49.  
In addition to the structural and metabolic changes observed in AD, various mood 
disorders, such as anxiety55–57 and depression58–60 have been associated with an increased risk of 
developing AD. A change in mood implies changes in monoaminergic neurotransmitters systems, 
for example the serotonin system61. Thus, changes in serotonin (5-HT) and its contribution in mood 
disorders62 suggests that alterations in this monoamine system could be a risk for developing AD. 
This reduction in serotonin is the result of lesions in the brainstem nuclei that synthesize this 
monoamine and can also be seen in early stages of AD63,64.  
Depression was found to increase a person’s risk for AD, with each subsequent depressive 
episode being associated with an increase in risk49,65. Although all the factors described show an 
association with the development for AD, a limitation that must be considered is that this 
relationship may be only correlational without any actual cause. As well, many of the risk factors 
are related to one another, and have a greater chance of being present together. Whether they have 
an additive effect, need to be present together for the risk to be increased, or mask the effect of 
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another inconspicuous agent is still not clear, but a reduction in serotonin levels have been 
consistently associated with AD63,64. 
 
1.2 Depression 
Of the AD risk factors described above, one of the most common is depression. In Canada, 
one fourth of residents will suffer from a form of depression severe enough to require treatment 
within their lifetime66. Depression is more prevalent in women and this trend is consistent from 
younger teens through to older adults67,68. Although everyone experiences some depressive 
symptoms at different points throughout their lives, in those that suffer from clinical depression 
the mood disorder intrudes upon the individual’s life. These people may experience constant 
sadness, anxiety, or an absence of feelings; changes in their regular sleep pattern resulting in too 
much or too little sleep; change in appetite, causing an associated weight change; loss of interest 
in their usual activities; irritability and restlessness; treatment resistant physical symptoms, such 
as digestive issues or chronic pain; difficulties concentrating, recalling memories, or making 
decisions; fatigue; feelings of worthlessness, hopelessness, or guilt; and suicidal thoughts69. In 
addition to these, males may experience “depressive equivalents” in place of emotional 
symptoms68. Men are more likely to show more irritability, anger, emotional numbness, and self-
distraction through workaholism, substance use, womanizing, and gambling68. Most of these 
symptoms are not identified as symptoms per se in the Diagnostic and Statistical Manual of Mental 
Disorders70; however, many of these behaviours can be ways to distract from depressive thoughts. 
Although depression is thought to occur more in women67, this may simply be due to how 
depression is defined for both sexes. 
As there are different types of depression, the causes of this mood disorder differ. For 
example, evidence has shown that clinical depression can be the result of a combination of 
environmental factors71, including stress, loss of family/friends, humiliation, failure, experiencing 
abuse, conflict, illness, financial crisis, and the physiological responses to these personal 
experiences. Experiences affect people differently, leading to the idea that there may also be 
genetic influences to depression72; possibly having the largest impact in a person’s vulnerability 
to depression. 
In addition, there are biochemical and anatomical differences in the brains of individuals 
with depression compared to mentally healthy controls. Differences in production and synaptic 
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availability of the monoamines dopamine, norepinephrine, and serotonin are likely the primary 
cause of depressive symptoms73. This notion was supported when compounds that increase 
availability of monoamines, by preventing their enzymatic breakdown, were shown to also reduce 
symptoms of depression73 and as such, the regions that synthesize these neurotransmitters, 
including the ventral tegmental area, locus coeruleus, and the raphe nuclei, have been targets of 
studies on depression73. Structural imaging has also shown that clinical depression is associated 
with enlarged lateral ventricles, reduced grey and white matter within the prefrontal cortex74, and 
decreased volumes of the amygdala75 and hippocampus76. 
 
1.3 Antidepressant drugs 
 A combination of psychotherapy and pharmacotherapy is the usual treatment of depression 
and allows both the dysfunctional biochemical pathways and the depressive thoughts they produce 
to be treated. In Canada from 2007 to 2011, 4.2% of men aged 25-44 and 8.2% aged 45-64 were 
prescribed at least one antidepressant drug. In both age groups, 9.3%, and 17.2%, of women were 
prescribed an antidepressant drug77. These numbers also include prescriptions for an 
antidepressant drug as an off-label treatment, e.g. for indications such as chronic pain or sleep 
disorders, and obviously does not consider individuals who were treated for depression using non-
pharmacological interventions (e.g. cognitive behavioural therapy). As changes in monoamine 
availability is likely the cause of depressive symptoms73, mechanisms for monoaminergic 
regulation are the targets for pharmacological therapy. A summary of commonly prescribed classes 
of antidepressant drugs can be seen in Table 2. 
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Table 1.2: Classes of antidepressant drugs and their putative modes of action. 
Antidepressant Drugs Mode of Action 
Monoamine oxidase 
inhibitors 
Block monoamine oxidases from breaking down monoamines 
within neurons, glial cells, and in the synapse78. 
Tricyclic 
antidepressants 
Associate with serotonin and noradrenaline uptake transporters, 
blocking transport of transmitters79. 
Selective serotonin 
reuptake inhibitors 
Prevent the uptake of serotonin by selectively inhibiting the 
serotonin transporter80. 
Serotonin noradrenaline 
reuptake inhibitors 
Inhibit the uptake of serotonin and noradrenaline, increasing their 
availability in the synapse81. 
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1.3.1 A brief history of the development of antidepressant drugs 
 Pharmaceuticals have been used as treatment for depression since compounds were found 
to have antidepressant properties in the 1950s. The first observation of antidepressant effects was 
after treatment with isonicotinylhydrazine, later called Isoniazid, which was being used to treat 
tuberculosis82. Iproniazid was then synthetically produced based on the structure of Isoniazid and 
found to have higher antitubercular properties in humans83. In addition to being a tuberculosis 
treatment, it was observed that Iproniazid caused heightened energy and improved mood in 
tuberculosis patients84. It began to be prescribed as an antidepressant drug and was found to cause 
an improved mood, increased interest and tolerance of social situations, and a healthy weight 
gain85. These compounds were found to alter levels of neurotransmitters, including serotonin, by 
inhibiting the enzyme responsible for serotonin degradation, i.e. monoamine oxidase (MAO). As 
such, they were named MAO inhibitors (MAOIs), and were the first category of pharmaceuticals 
used to treat depression86.  
 As with most medications, there were many side effects associated with their use87–89, thus 
further research was done. Chlorpromazine, a compound originally synthesized in 1883 for the 
textile industry, was found to have antidepressant properties when tested on patients with psychotic 
symptoms90. The structure-activity relation studies of Chlorpromazine led to the development of 
the first tricyclic antidepressant (TCA) drug. Imipramine, was the original serotonin uptake 
inhibitor, which led to the increased availability of serotonin within the synapse and was available 
as an antidepressive treatment by the 1960s91.Yet, TCA drugs, because they also targeted 
histaminergic and cholinergic systems, also had unwanted side effects such as dizziness, lethargy, 
and some cognitive changes. 
  This led to the development of more selective reuptake inhibitors. A category of 
antidepressant drugs that was developed shortly after the MAOIs and TCAs were the tetracyclic 
antidepressant drugs; however, this class has not remained a popular option for treatment.  
 The first class of antidepressant drugs designed to target a specific transporter were the 
selective serotonin reuptake inhibitors (SSRIs)92. The first of the SSRIs developed was Fluoxetine; 
it increased serotonin availability by inhibiting its uptake from the synapse back into the 
presynaptic neuron80. Fluoxetine was shown to successfully reduce depressive symptoms 
following its introduction in the early 1980s. However, Fluoxetine treatment had a delay in 
response time and roughly 30% of patients were unresponsive to the treatment93.  
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 As it had been hypothesized that both serotonin and noradrenaline have roles in 
depression81, another category of compounds was produced that would enhance the availability of 
both monoamines within the brain. This class of antidepressant drugs is known as the serotonin-
noradrenaline reuptake inhibitors (SNRIs) and they can bind to both serotonin and noradrenaline 
reuptake transporters94. 
 
1.3.2 Categories of antidepressant drugs 
1.3.2.1 Monoamine oxidase inhibitors 
The first antidepressant drugs discovered were the MAOIs86, specifically with the use of 
Iproniazid. As the name of this category of antidepressant drugs suggests, these drugs prevent the 
monoamine oxidase (MAO) enzyme from breaking down monoamines in neurons, glial cells, and 
within the synapse. The MAOs degrade excess neurotransmitters from these areas and allow for 
regulation of appropriate levels of neurotransmitter availability around neurons. For example, 
serotonin is broken down to serotonin aldehyde (5-HIAL), then is converted to 5-
hydroxyindoleacetic acid (5-HIAA) by aldehyde dehydrogenase (ALDH)95. This increase in 
synaptic concentration of neurotransmitters potentiate neurotransmitter binding to the respective 
receptors78. There are two forms of this enzyme: MAO-A and MAO-B. The isoenzymes can 
metabolize many compounds, but both have higher affinities for certain monoamines. MAO-A 
metabolizes serotonin, adrenaline, and noradrenaline, but has higher affinity for serotonin and 
noradrenaline; while MAO-B is able to break down dopamine, benzylamine, and β-
phenylethylamine96, with a preference for the latter two97. As well as breaking down different 
monoamines, the two isoenzymes are found in different neurons. MAO-A is found in 
catecholaminergic neurons98 and is more abundant in the locus coeruleus, an area of the brain with 
the greatest number of noradrenergic neuronal cell bodies99. In contrast, MAO-B is found in 
serotonergic neurons, histaminergic neurons, and in glial cells98, therefore, its greatest abundance 
is in the raphe nuclei, which is where all of the brain’s serotonin cell bodies are found99. As stated, 
these enzymes control monoamines in and around the neurons. If any of these neurotransmitters 
are produced in concentrations that are too high to be regulated locally (through breakdown by 
intracellular MAOs after being transported back into the neuron) and are allowed to diffuse into 
an adjacent synapse, then extracellular MAOs will degrade any of the diffused neurotransmitter 
excess so that they cannot impede proper signalling or act as false neurotransmitters at these 
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adjacent sites100. In addition to neurons, MAOs are also expressed in many peripheral tissues where 
these isozymes typically are present in the same tissues and organs101. 
 The original MAOIs were successful at reducing depressive symptoms, however they did 
have some unwanted side effects, which arose due to the irreversible inhibition of both MAO-A 
and MAO-B102. Inhibiting both isoenzymes prevents the breakdown of many monoamines, 
allowing their availability to increase. Tyramine is one such monoamine that accumulates upon 
MAO inhibition and can represent a problem in individuals with a diet that includes food and 
beverages that are high in tyramine by ingesting foods and beverages including soft cheeses, 
fermented sausages, yogurt, wine, and beer containing yeast103. Toxic levels of unprocessed 
tyramine can displace other monoamines with similar structure (including dopamine, adrenaline, 
and noradrenaline) from vesicles, and bind to their respective receptors in their place. This 
displacement can lead to vasoconstriction, causing a rise in blood pressure and heart rate103. Other 
side effects that have been observed due to tyramine accumulation are jaundice, nephrotoxicity, 
and fatal hepatic cell damage87–89. 
 As it was known that MAO-A was the isoform associated with the antidepressant effect, 
when MAOIs were developed, they were targeted to bind to the A isoenzyme selectively, but 
reversibly104. The recovery from MAOIs that irreversibly bind both MAO-A and MAO-B is 
dependent on the time it takes neurons to synthesize new MAOs to metabolize the 
neurotransmitters. MAOIs can be eliminated faster than the body can synthesize new MAOs, thus 
these antidepressant drugs are not efficient103. However, MAOIs that can reversibly inhibit MAO-
A have a shorter reaction time also allowing for a quicker recovery rate since the drug can 
dissociate from the enzyme. As dissociation occurs, more of the MAOI can be metabolized and 
eliminated103, allowing the newer generation of MAOIs to have fewer negative side effects 
compared to the first generation. As the newer MAOIs allow MAO-B to metabolize tyramine104, 
the potential for a hypertensive response is also reduced103. Although there are some extra 
precautions that need to be taken when using MAOIs to treat depression, they can still be very 
successful at combating depressive symptoms. 
 
1.3.2.2 Tricyclic antidepressant (TCA) drugs 
The TCA Imipramine was observed to have antidepressant effects around the same time as 
Iproniazid, giving more support to the theory that increasing the availability of monoamines is a 
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way to treat depression81,105.  TCAs accomplish this by binding to serotonin and noradrenaline 
uptake transporters79, and preventing the uptake of these monoamines into the presynaptic terminal 
where they might be degraded by MAO. However, TCAs are not very selective as they can also 
bind to serotonin receptors106, muscarinic cholinoceptors107, histamine receptors108, and α-
adrenoceptors109. The promiscuity of these compounds is likely what causes the range of side-
effects seen in patients prescribed TCAs. As stated above, the side effects of these compounds 
include dizziness, vomiting, weight change, indigestion, fatigue, constipation, headaches, and 
decreased sex drive110. 
 
1.3.2.3 Selective serotonin reuptake inhibitors (SSRIs) 
As serotonin was known to have a role in depression81, new antidepressant drugs were 
developed to specifically target and inhibit serotonin reuptake transporters. The first SSRI 
designed was Fluoxetine80, which continues to be widely prescribed to treat depression and more 
recently for many other off-label disorders and symptoms. The treatment was successful in many 
patients and was associated with very few complications; however, the rate of treatment resistance 
was not reduced with the introduction of SSRIs111 indicating that there were still unexplained 
differences between individuals (or the type of depression that they suffered from)112,113.  
 
1.3.2.4 Serotonin-noradrenaline reuptake inhibitors (SNRIs) 
Availability of both serotonin and noradrenaline were reported to be simultaneously 
reduced in depression. Since some patients were not responsive to SSRIs, new compounds were 
developed to increase the availability of both monoamines81. To accomplish this, SNRIs were 
designed to bind to both serotonin and noradrenaline reuptake transporters. The initial compounds 
in this drug category had variable affinities for these targets114–116. In addition, these compounds 
are not as selective as SSRIs and depending on the actual SNRI, they are able to bind secondary 
receptors114–116. The lack of selectivity accounts for the range in tolerability in depressive 
patients117,118.  
All antidepressant drugs described above have been shown to alleviate the symptoms of 
depression, although there is no one compound, or class of compound, that has been found to have 
a 100% success rate at improving depressive symptoms in all patients (i.e. regardless of type of 
depression). As well, when remission does occur, it is typically after weeks of treatment and does 
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not occur with the first treatment tried. Trial-and-error is often used to determine which medication 
is best tolerated in the individual. While treating the depressive symptoms present, some side 
effects still accompany pharmacotherapy such as nausea, constipation, headaches, fatigue, weight 
changes, or a reduced sex drive110,119. 
 
1.3.3 Serotonin Transporter (SERT) 
SERT is the target for antidepressant uptake inhibitors, such as TCAs, SNRIs, and SSRIs; 
the latter of which has the greatest selectivity and specificity for this transporter. Evidence suggests 
that there are distinct binding sites on the transporter for TCAs and for SSRIs, as the uptake 
inhibitors do not produce consistent effects within patients120,121. Although the compounds can act 
quickly and inhibit serotonin uptake, the antidepressant effects only occur after more than a week 
of treatment122. The delay suggests that the antidepressive actions are the result of long-term 
adaptive changes, including down-regulation or desensitization of receptors, caused by the 
increased availability of serotonin122.  
As with other related neurotransmitter transporters, SERT has a 12-transmembrane domain 
structure123.  This transporter is bidirectional, but typically transports one Na+ and one Cl- with 
every serotonin molecule from the extracellular space into the pre-synaptic neuron, with the 
removal of one K+ ion into the synaptic cleft122,124. SERT terminates serotonin neurotransmission 
by removing the monoamine from the synaptic cleft back into the presynaptic cell125 to be either 
metabolized by MAO and forming 5-HIAA or packaged into new secretory vesicles by the 
vesicular monoamine transporter126. The region of the brain with the greatest abundance of 
serotonergic neurons is the raphé nucleus (localized within the brainstem)126, thus this transporter 
is more prominent in these neurons. 
There are some studies showing that sex does not have an effect on the efficacy of 
antidepressant drugs127–129, however, many studies have shown that females show greater 
improvement in mood when treating their depression with an SSRI130–133 and treatment in males 
is more successful with TCAs131,134–136. The sex difference in efficacy suggests that either SERT 
is not structurally the same when comparing females and males or that the transporters are the 
same but are not modulated by other proteins the same way between the sexes. This is further 
supported by the theory that there are two binding sites on the uptake transporter. Their affinity 
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may be different between the two sexes, allowing TCAs to be more successful in males and SSRIs 
to produce better effects in females. 
 
1.3.4 The effects of metabolism  
Many of the antidepressant (uptake inhibitor) drugs have active metabolites, so it is 
important to consider how the liver might contribute to the profile of any antidepressant drug. 
Although all tissues have some metabolic capabilities, the liver is the main organ involved in 
metabolic processes137. Within the liver, cytochrome P450 enzymes are a superfamily of 
hemethiolate enzymes that mainly metabolize xenobiotic compounds, including clinically used 
drugs138,139. Of the many polymorphic P450 enzymes, six are involved in the metabolism of most 
clinically relevant antidepressant drugs: CYP2D6, CYP3A4, CYP2C9, CYP2CI9, CYP1A2, and 
CYP2E1137. 
There are many factors that influence the rate a compound is metabolized and, therefore, 
affecting the pharmacokinetics of the drug. Aside from the range of genetic polymorphisms of 
digestive enzymes, age and sex are two important factors that can affect a person’s metabolism140–
142. This is especially important for prodrugs, which require transformation to their active 
metabolites for activity, and for compounds that have toxic metabolites143. 
 
1.3.4.1 Metabolism and age 
 The increase in life expectancy, reflected in lower mortality rates, is resulting in an aging 
population144. An older population brings with it many physiological changes and deterioration145, 
most of which negatively affect metabolism. Of these, alterations in liver function exert a great 
influence on the “aging” physiology and this affects how drugs are metabolized and cleared from 
the body141. With age comes a decrease in organ volume that can range from 20-40%146 and 
reduced blood flow, slowing the delivery of the compound to the organ and its metabolism by 40-
60%141. Clearance of drugs is more dependent upon the latter; if the drugs cannot be transferred 
efficiently to be metabolized (e.g. in the case of Fluoxetine, it is absorbed from the gastrointestinal 
tract and is delivered to the liver to be metabolized137), that will greatly influence their 
pharmacokinetics (i.e. how drugs are distributed throughout the body) as well as the types of 
compounds produced and their relative availability. For example, nor-Fluoxetine, the major 
demethylated metabolite of Fluoxetine, has a much longer half-life (e.g. seven to fifteen days) in 
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comparison to Fluoxetine (e.g. one to three days)147, and both are found to have similar 
mechanisms of actions and affinities for SERT. Since metabolism slows with age, this breakdown 
would be relatively slower in older individuals, who will display lower levels of nor-Fluoxetine. 
Interestingly, treating older patients with Fluoxetine may be safer because of the slower breakdown 
of the drug,148 allowing for less nor-Fluoxetine to be produced. 
 
1.3.4.2 Metabolism and sex 
 The differences in anatomy and tissue composition between the sexes result in differences 
in the ability to metabolize compounds. Sex differences in liver metabolism, hormone levels, body 
weight, volume of plasma, plasma protein levels, gastric emptying, gastric acid secretion, enzyme 
activity, and body fat are known to affect the pharmacokinetics of a drug142. Antidepressant drugs 
are lipophilic in nature and, as such, have an affinity for adipose tissue; women tend to have a 
greater percentage of body fat and adipose tissue, which could explain the greater distribution of 
antidepressant drugs found within a female body149. Specifically, Fluoxetine is highly lipophilic 
and, has a longer half-life than most other SSRIs. In addition, the half-life of nor-Fluoxetine is 
much longer, and brain levels of this compound have been found to be 2-fold elevated over 
Fluoxetine at steady state150. Women also metabolize Fluoxetine to nor-Fluoxetine faster than 
men151, and the metabolite remains longer in females152, possibly due to slower gastric clearance 
and acid secretion from changes in estrogen153.  
 Inconsistencies in metabolism studies could be due to methodological differences used. 
These include the demographic studied, class of antidepressant drug used, variation in the 
treatment regimen, statistical analysis, and age of female patients142. The varied estrogen levels 
throughout the onset and duration of menopause could have great effects on the efficacy of a drug 
and its metabolism. As stated above, estrogen levels have been found to influence gastric 
motility142. If the participants in the studies were not at the same stage of their menstrual cycle 
with similar sex hormone levels, differences in metabolism could be present. This may be another 
factor that needs to be considered, otherwise comparisons between the individuals in the study 
may be inaccurate. 
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1.4 Project Goal 
 This project aims to determine the effect of SSRIs on the intracellular accumulation of Aβ 
in a cell and whole organism models.  
 
1.4.1 Caenorhabditis elegans as a model of AD 
 The nematode, C. elegans, has a short lifespan of around 25 days, which provides an 
excellent model for aging and neurodegeneration studies. Its rapid turnover from embryo to 
reproductive mature adult is a benefit for genetic manipulation and high sample sizes in a short 
period of time. In addition, synchronized generations can be easily obtained through a bleaching 
process of multigenerational populations that kills larvae and adults leaving only the embryos 
(protected by their egg shells)154. Since C. elegans have only a small number of neurons compared 
to a human brain, the muscle cells provide an effective predictive in vivo model to test the effects 
of antidepressant drugs on the accumulation of Aβ and investigate the genetic machinery 
modulating its effects in an intact organism. This nematode has been extensively used as an entry 
model system in aging studies because it offers a faster and suitable platform to screen for the 
genetic and cell biology underpinnings of aging cells.  
 C. elegans does express an ortholog of APP, APL-1 (amyloid precursor-like-1); however, 
APL-1 does not have β-secretase (BACE) sites155 and because of this, APL cannot be cleaved to 
an Aβ variant. As well, this species does not express a BACE ortholog155. This is beneficial for 
surrogate AD studies because transgenic worms have been constructed to express human 
sequences producing Aβ peptide variants155,156, enabling the study of any effects of the protein 
with fewer interfering endogenous factors. The worm strains utilized in this project express one of 
two Aβ peptide variants, Aβ1-42 or Aβ3-42, and are controlled by a muscle promoter. As the 
transgene expression is restricted to muscle cells, this results in a progressive paralysis phenotype 
to be analyzed. The degree of paralysis can be used to screen for effects of drugs or mutations on 
Aβ accumulation. 
 
1.4.2 Cell culture as a model of AD 
 As with C. elegans, cell cultures are advantageous model systems for studying the 
molecular hallmarks of AD. Cell culture allows the systemic and behavioural effects observed in 
live worms to be translated to a mammalian system and studied in relevant cell types at the 
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molecular level. Although the worms are suitable to study neurodegenerative disorders, the 
transgenic strains used in this study were produced to over-express Aβ in their muscle cells, which 
makes it difficult to extrapolate to the neuronal context. Conversely, cell culture can directly model 
these processes in neuronal-like cells, which are more comparable to the accumulation seen in the 
human brain. As well, this model can be used to quantitatively study the role of SSRIs in the 
dynamic changes of Aβ localization, intracellularly or, if exported, in the media.  
There are AD mouse models available that can be used to study the effects in a mammalian 
organism closer in evolutionary divergence to humans; however, C. elegans and cell culture 
together provide models that are more easily manipulated and provide a more direct method to test 
the hypotheses. C. elegans allow for functional assays to study the effects of SSRIs on Aβ-
mediated toxicity and mammalian cell culture can be used to display whether Aβ can be exported. 
As this study focuses on the accumulation of Aβ as a contributing factor to the development of 
AD, the use of a mouse model would have produced more challenges to overcome. Firstly, mouse 
models can take from 2 to 15 months to age enough for plaque deposition and from 3 to 17 months 
for cognitive deficits to occur157, and the timeline varies between the mouse lines. Because of the 
additional time required, the sample size would suffer. Secondly, a mouse is much more complex 
than a nematode; although there are models of both mice and C. elegans that lack the serotonin 
transporter, in a mouse there would be more additional effects to consider. For example, mice that 
are homozygous for the null mutation of SERT produce increased anxiety-like behaviours158, 
which could interfere in behavioural assays to test for depressive symptoms when mimicking the 
pharmacological inhibition of SERT. As stated, worms have many conserved pathways that can 
be studied and a less complex nervous system, allowing for fewer possible interfering targets. 
 
1.4.3 Project Rationale  
An association exists between depression and AD, with those suffering from depression 
early in life having an increased risk for AD later in life159. In addition, both depression and AD 
are associated with a decrease in serotonin and noradrenaline. In AD this reduction of monoamine 
transmitters is the result of brainstem lesions, which are present early in disease progression; in 
patients with comorbid depression and AD, this damage is exacerbated63,64. However, a study by 
Kessing and colleagues (2009), suggests that any risk of AD associated with a diagnosis of 
depression may be exacerbated by the type of treatment used for depression rather than depression 
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itself120. It was found that individuals with depression who developed dementia were twice as 
likely to have been treated with an SSRI compared to individuals who did not develop AD120. 
SNRIs displayed a lesser risk of 1.5x; and TCAs showed no effect or reduced the risk of AD120,160. 
All the people studied had been diagnosed with clinical depression, therefore depression itself must 
not be the factor amplifying their risk for AD, as not all showed the same risk for AD. Aside from 
these findings, the literature discussing a potential association between Aβ accumulation and 
SERT is minimal. 
The use of antidepressant drugs to combat depression and off-label purposes is very 
common77, and with the continued use of these medications, chronic side effects will begin to be 
observed. The acute effects of compounds can be evident after the initial treatments, but long-term 
effects are not known until the drug has been in use for many years. As our knowledge about 
antidepressant drugs grows, changes may be required in prescribing compounds for treating 
depression. Some studies have produced data suggesting that chronic use of antidepressant drugs 
is associated with dementia, with people suffering from dementia being twice as likely to have 
taken antidepressant drugs compared to individuals that did not have dementia161. As well, the 
earlier depression occurs in an individual, the probability for antidepressant drug use and possible 
polypharmacy will increase. Of the people who experience one depressive episode, 50% will suffer 
a second event, and 80% of those individuals will have at least one more70. Chronic depression 
can result in chronic antidepressive treatment, which will just have compounding effects and 
further risk for polypharmacy. 
SERT is thought to only be involved with the transport of serotonin, however, it has been 
shown that α-synuclein, which typically is associated with Parkinson’s disease and the dopamine 
transporter162, was able to bind to SERT,163 suggesting that there may also be a link to Parkinson’s 
disease. α-Synuclein was found to directly bind to SERT and cause negative modulation of the 
transporter by competing with serotonin163. An argument could be made that as serotonin is derived 
from tryptophan, its size would be comparable to an amino acid, but, since Aβ peptides range from 
40-42 amino acids in length, the possibility that Aβ could be cleared through SERT or associate 
with this transporter is unlikely. However, the theory of the association between SERT and Aβ 
cannot be eliminated based on the size of this peptide given that α-synuclein can interact and 
modulate SERT163, and is a much larger peptide consisting of 140 amino acids164. If proteins 
involved with the pathology of AD, such as Aβ, can be removed from the cell through this 
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transporter, treatment with a compound that blocks the transporter would also prevent the removal 
of this toxic protein. Thus, treatment with SSRIs would prevent Aβ transport, aiding in intracellular 
accumulation of Aβ and facilitating the formation of amyloid plaques, displayed in Figure 1. The 
progression of experiments performed in this study are discussed in Figure 2. 
 
1.4.4 Research Hypothesis 
SSRI treatments, particularly Fluoxetine and nor-Fluoxetine, may contribute to AD by 
enhancing the accumulation of intracellular Aβ peptides through inhibition of SERT. 
 
1.4.5 Project objectives 
 The specific objectives studied are: 
1) To determine if Fluoxetine and nor-Fluoxetine treatments lead to an 
intracellular accumulation of Aβ in a C. elegans transgenic model. 
2) To determine if Fluoxetine and nor-Fluoxetine prevent Aβ removal via 
SERT in mammalian cell cultures.  
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Figure 1.1: The proposed effect of SSRIs on Aβ deposition in neurons. 
The role of SSRIs is to bind and inhibit SERT from being able to transport serotonin into the 
presynaptic neuron, increasing the availability of this monoamine within the synapse. It is 
theorized that SERT does not select only for serotonin and that Aβ is moved out of the neuron 
through these transporters, seen in the left panel. The right panel depicts inhibition of Aβ 
movement and the resulting accumulation of the toxic peptide within the presynaptic neuron, near 
the membrane of the cell. 
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Figure 1.2: Experiment flowchart. 
The first model used was C. elegans (depicted in dark gray), to show the effects of Fluoxetine or 
nor-Fluoxetine treatment on the accumulation of Aβ by studying the paralysis phenotype produced. 
To optimize the strategy utilized, first a paralysis assay was employed to determine if there was a 
difference in paralysis rate with Fluoxetine or nor-Fluoxetine treatment. However, this assay only 
allows qualitative data to be collected, so a thrashing assay was used to quantify paralysis by 
analysing thrashing behaviour. To ensure that the worm analogue of SERT, MOD-5, interacts with 
SSRIs, a strain that expresses Aβ1-42 was crossed in a mod-5 mutant. This new strain was used to 
molecularly mimic the pharmacological inhibition of the serotonin transporters with a thrashing 
assay. As SSRIs alter serotonin availability, a strain that expresses Aβ1-42 was cross-bred to also 
have a tph-1 (tryptophan hydroxylase) mutant background. This mutation prevents serotonin from 
being produced by lacking tryptophan hydroxylase. A thrashing assay was used to determine if 
altering the levels of serotonin changes thrashing behaviour. The second model, seen in light gray, 
is mammalian cell culture, used to test the location of AB with Fluoxetine treatment. The cells 
were transfected with one of two types of human APP. Immunoprecipitation and Western blotting 
were then used to determine whether the AB could be found in the media, or if its transportation 
was prevented with treatment with Fluoxetine. As well, immunoprecipitation and Western blots 
were used to look for any interaction between Aβ variants and SERT.  
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2 Materials and Methods 
2.1 Materials 
2.1.1 C. elegans Strains 
Table 2.1: C. elegans strains utilized throughout this study. 
Strain Genotype Source Reference Purpose 
CL2122 dvIs15 [(pPD30.38) 
unc-54(vector) + 
(pCL26) mtl-
2::GFP] 
Chris Link; 
University of 
Colorado 
Fay et al., 
1998165 
Control strain for 
paralysis and thrashing 
assays 
Cl2120 dvIs14 [(pCL12) 
unc-54::A-beta-1-
42 + (pCL26) mtl-
2::GFP] 
Chris Link; 
University of 
Colorado 
Fay et al., 
1998165 
To study the effects of 
SSRIs on Aβ3-42 
GMC101 dvIs100 [unc-
54p::A-beta-1-
42::unc-54 3'-UTR 
+ mtl-2p::GFP] 
Gawain McColl; 
The Florey Institute 
of Neuroscience 
McColl et 
al., 2012155 
To study the effects of 
SSRIs on Aβ1-42 
CB61 dpy-5(e61) I Sydney Brenner; 
Medical Research 
Council Laboratory 
of Molecular 
Biology 
Brenner S, 
1974166 
Used in crossing 
schemes 
MT9772 mod-5(n3314) I H. Robert Horvitz; 
MIT 
Ranganathan 
et al., 
2001167 
To test whether SSRIs 
act on the worm 
analogue of SERT 
CB128 dpy-10(e128) II Sydney Brenner; 
Medical Research 
Council Laboratory 
of Molecular 
Biology 
Brenner S, 
1974166 
Used in crossing 
schemes 
MT15434 tph-1(mg280) II H. Robert Horvitz; 
MIT 
Sze et al., 
2000168 
To test whether 
serotonin has a role in 
the reduced thrashing 
phenotype 
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Table 2.2: C. elegans genes 
Gene Protein/Role 
Mod-5 Serotonin transporter 
Tph-1 Tryptophan hydroxylase 
Dpy-5 Group I procollagen; when mutated produces a dumpy (smaller and 
wider than WT worms) phenotype 
Dpy-10 Cuticle collagen protein; when mutated produces a dumpy (smaller and 
wider than WT worms) phenotype 
DvIs100 Transgene consisting of a UNC-54 muscle promoter vector, Aβ1-42, and 
a green fluorescent protein marker 
DvIs14 Transgene consisting of a UNC-54 muscle promoter vector, Aβ1-42 
which gets cleaved to Aβ3-42, and a green fluorescent protein marker 
DvIs15 Transgene consisting of a UNC-54 muscle promoter vector and a green 
fluorescent protein marker 
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2.1.2 Cell Lines 
Table 2.3: Cell lines used throughout this study. 
Cell Line Organism Tissue Morphology Reference 
HEK293 Human Embryonic kidney Neuronal-like ATCC: CRL-3249 
HT22 Mouse Hippocampus Neuronal Maher and Davis, 1996 
SH-SY5Y Human Neuroblastoma Epithelial ATCC: CRL-2266 
N2a Mouse Neuroblastoma Neuronal ATCC: CCL-131 
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2.1.2.1 Cell pellets for initial SERT screen 
Before determining which cell line would be used to test the effects of Fluoxetine and nor-
Fluoxetine, a variety of human and mouse cell lines were screened for levels of SERT. 
 
2.1.3 Plasmids 
Three plasmids carrying different alleles of APP were used to transfect cells: pcDNA3.1 
(Invitrogen) empty vector, pcDNA3.1/APPWT, and pcDNA3.1/APPSwe/Ind. APPWT is the common 
form found within humans, while APPSwe/Ind is an allele that carries two mutations within APP (a 
two amino acid substitution and a point mutation, respectively) that results in a greater production 
of Aβ. The plasmids containing the APP inserts were cloned using Hind-III at the 5’ end and Xba-
I at the 3’ end to contain APPWT or APPSwe/Ind. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
27 
 
2.1.4 Equipment and Reagents 
Table 2.4: Reagents 
Reagent Manufacturer Catalogue Number Lot Number 
Tris Base Fisher Scientific BP154-1 164826 
Glycine Fisher Scientific BP381-1 166210 
SDS J.T. Baker L050-07 E07619 
Methanol Fisher Scientific AU52-4 171488 
Sodium Chloride Fisher Scientific S271-3 167532 
Glycerol Anachemia AC-4674 770328R 
β-mercaptoethanol Sigma M-3148 102K0025 
Bromo-Blue Sigma B-5525 4143657 
Sulfuric Acid Fisherbrand UN1830 114275 
Bistris Sigma 1B9754 SLBH8220V 
Bicine Sigma B8660 SLBR5204V 
Triton X-100 Sigma 9002-93-1  
30% Acrylamide/Bis Bio-Rad 161-0158  
40% Acrylamide/Bis Bio-Rad 161-0144  
Urea Sigma U5378-1KG SLBH3423V 
Isopropanol Fisher Scientific A416-4 143620 
DMEM (1X) Gibco 11885-084 1848586 
DPBS (1X) Gibco 14190-144 1806048 
DMEM/F12 Gibco 11330-032 1869010 
Opti-MEM+GlutaMAX Gibco 51985-034 1868987 
Recovery Cell Culture 
Freezing Medium 
Gibco 12684-010 18855679 
Fetal Bovine Serum Gibco 12483-020  
Trypsin/EDTA Gibco R-001-100  
Bovine Serum Albumin Sigma A3912-100G SLBL5766V 
Total Protein Kit, 
Micro Lowry, 
Peterson’s Modification 
Sigma-Aldrich TP0300-1KT 020M6096 
Qiagen HiSpeed® 
Plasmid Maxi Kit 
Qiagen 12663 157037836 
PageRuler Prestained 
Protein Ladder 
Thermo Scientific 26616 00568726 
Specter Low Range 
Ladder 
Thermo Scientific 26628 00551160 
C-TERM antibody Sigma A8717 43M4B16 
6E10 Bio Legend 803002 B226151 
4G8 Bio Legend 800702 B198888 
ST45A5 Santa Cruz  L1316 
22C11 EMD Millipore MAB348 2793862 
Anti-mouse 800 LI-COR 925-32210 C70712-11 
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Protein A Sepharose 
Beads 
GE Healthcare 17-5280-02 10229487 
Protein G Sepharose 
Beads 
GE Healthcare 17-0618-05 10232495 
Goat-anti-mouse IgG Bio-Rad 170-6516  
TEMED Bio-Rad 1610-0801  
Lipofectamine Invitrogen 11668-019  
SERT Biorbyt Orb13226  
Sodium Chloride BioShop SOD001.205 6E43489 
Peptone BioShop PEP403.500 6D43152 
Agar Powder Anachemia 02116-380 16E106578 
Calcium Chloride BioShop CCL555.500 2A23595 
Magnesium Sulfate BioShop MAG513.500 1L22952 
Ethyl Alcohol 95% Commercial Alcohols P016EA95 24061 
Cholesterol Alfa Aesar A11470 I14W043 
Potassium Phosphate 
Monobasic 
BioShop  PPM302.1 6D43352 
Potassium Hydroxide BioShop PHY202.1 1C20501 
Sodium Phosphate 
Dibasic 
Sigma-Aldrich 57907-500 086H0066 
Glycerol Fisher BioReagents BP229.1 168402 
Javex [Commercial Product]   
Bio-Tryptone BioShop TRP402.500 6D43153 
Yeast Extract BioShop YEX401.500 1L22941 
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Table 2.5: Equipment 
Equipment Manufacturer Model 
Fume hood H.H. Hawkins LTD 115/230 
Stirrer and Hot Plate Corning PC-351 
Power Pac Bio-Rad Power Pac 300 
Water Bath Fisher Scientific 2340 
Centrifuge (15ml tubes) International Equipment Co.  
Bio-Safety Cabinet Microzone Corporation Bio Klone 2 
Cell Culture Incubator Thermo Scientific HERACell VIOS 160i 
Microcentrifuge Bio-Rad S586354 
Heat Block Fisher Scientific Isotemp 2001 
Scale Mettler Toledo M51045 
Rocker  VWR Standard Analog Rocker 
-80°C Freezer Thermo Scientific Forma 88000 Series 
Spectrophotometer Molecular Devices Spectra Max M5 
LI-COR Mandel Odyssey 
Nanodrop Thermo Scientific NANODROP 2000c 
Vortex Scientific Industries Vortex Genie 1 
Impulse Sealer Uline KF-300H 
Incubator Fischer Scientific Isotemp 
Shaking Incubator Thermo Scientific MaxQ 4000 
Media Dispenser Wheaton Unispense 
Microscope Nikon Nikon SMZ 745 
Light Transformer Nikon Transformer XN 
Fluorescence Microscope Nikon Nikon H550L 
Transformer Lumen Dynamics X-CITE Series 120 
Pipet-Aid Drummond  
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2.2 Methods 
2.2.1 C. elegans maintenance and crossing strategies 
2.2.1.1 Maintenance 
All C. elegans strains were maintained on 60mm plates with normal growth medium 
(NGM) at 16°C in a Fisher Scientific Isotemp® incubator and fed the OP50 strain of E. coli. The 
coding sequence to express Aβ1-42 or Aβ3-42 follows the unc-54 muscle enhancer and includes a 
green fluorescent marker (the complete transgenes are dvIs100 or dvIs14, respectively). Strains 
were maintained at 16ºC prior to the paralysis and thrashing assays. Protein accumulation increases 
considerably at higher temperatures (25°C) and worms display a progressive paralysis 
phenotype155,156. To ensure synchronous populations, plates were kept at the same temperatures 
and experiments with different strains/treatments were performed in parallel on the same days.  
 
2.2.1.2 Breeding  
 To test whether Fluoxetine and nor-Fluoxetine effects on thrashing behaviour depended on 
proper transport and serotonin synthesis, strains expressing muscle Aβ1-42 (dvIs100) in mod-5 
(serotonin tranporter) and tph-1-depleted (tryptophan hydroxylase) backgrounds, respectively, 
were constructed. 
 
2.2.1.2.1 Generating males 
Males were isolated from the progeny of heat shocked young adult hermaphrodites that 
were incubated at 30ºC for 4 hours169. Heat shock at this temperature increases frequency of X 
chromosome non-disjunction during meiosis without compromising fertility. Monosomic X0 
worms in C. elegans develop as normal males. Rare males (X0) that resulted from non-disjunction 
events in XX oocytes were isolated from the progeny of heat shocked worms and subsequently 
mated with virgin hermaphrodites. Upon mating, a 1:1 XX/X0 (hermaphrodite/male) progeny ratio 
can be generated and 50% male populations maintained. 
 
2.2.1.2.2 Generating mod-5;dvIs100 worms 
To ensure that the SSRIs being tested were indeed acting on the serotonin transporter, the 
effects of genetically inhibiting its function in the worm was tested. The hypothesis was that any 
genetic inhibition of SERT function would mimic the pharmacological inhibition seen with 
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Fluoxetine and nor-Fluoxetine. The steps to achieve this cross are displayed and discussed in 
Figures 3 and 4. An intermediate strain was required in the production of mod-5;dvIs100 and the 
steps in the cross strategy are displayed in Figures 3 and 4. 
Although dvIs100 males (GMC101; Aβ1-42 transgene) could be crossed with mod-5 
hermaphrodites (MT9772) to produce mod-5;dvIs100 worms, it would be difficult to identify mod-
5 animals from siblings heterozygous for mod-5, as mod-5/+ worms are overtly WT and only 
display abnormal behaviour in response to exogenous serotonin. To evade the need for molecular 
screening for the mod-5(n3314) mutations or, alternatively, individually testing progeny for 
serotonin hypersensitive phenotypes, the cross strategy took advantage of a phenotypic marker 
allele, dpy-5(e61) linked to  the mod-5 locus on chromosome I. Dumpy worms are viable, though 
significantly smaller than the WT which allows for identification of dpy-5 homozygotes on plates 
with non-dumpy worms. The first part of this strategy required the introduction of the Aβ-
containing transgene (dvIs100) into the dpy-5 background (Figure 3) while in the subsequent steps, 
the dpy-5 mod-5 + chromosome was selected out of the self-fertilized progeny of dpy-5 mod-5 
+/dpy-5 + mod-5 hermaphrodites, therefore eliminating any other unrecombined genotype with 
the exception of dpy-5+ mod-5 homozygotes, as shown in Figure 4. 
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Figure 2.1: Cross scheme for generating dpy-5;dvIs100 worms. 
Although the GMC101 and MT9772 strains could be crossed to produce a mod-5;dvIs100 mutant 
worm, it would be difficult to determine which worms produced were homozygous for the mod-5 
mutation, which were heterozygous, and which were the product of no cross occurring. To avoid 
this eventuality, an additional step was required so that there would be a phenotype to select against 
and allow for selection of the mod-5 mutation. Male GMC101 worms and hermaphroditic CB61 
worms were allowed to mate on two mating plates to breed overnight. (Mating plates are regular 
NGM plates with a small drop of OP50 in the center so that the worms stay in the same area, 
increasing the frequency of meetings.) The next day, the CB61 worms were picked onto individual 
seeded NGM plates (called singling) to isolate their progeny form the other progeny of the other 
“mothers”. Once the eggs were laid, the “mother” was removed so that only F1 progeny was on 
the plates. If the cross has occurred, the F1 generation will all be dpy-5+/+dvIs100 and appear non-
dumpy, with possibly faint green fluorescence along the body muscle due to the GFP marker gene 
within dvIs100. F1 worms are then singled, then the F2 generation was scored for worms that 
showed a dumpy phenotype and had green fluorescence along their body muscle to single. These 
worms were either homozygous for both dpy-5 and dvIs100, or homozygous for dpy-5 and 
heterozygous for dvIs100. To ensure the worms are homozygous for both genes, the F3 generation 
was scored for progeny that all show a dumpy phenotype and fluoresce green. These worms were 
dpy-5;dvIs100 and the strain named CEC216. 
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Figure 2.2: Cross scheme for generating mod-5;dvIs100 worms. 
To complete the second portion of the cross to have worms that produce Aβ1-42 that also lack the 
serotonin transporter, MT9772 males and hermaphroditic CEC216 worms were crossed overnight. 
The next day, CEC216 worms were singled onto seeded NGM plates, and once they had laid their 
eggs, the “mother” was removed. If the cross occurred, all worms are mod-5 +/+ dpy-5;dvIs100/ 
+. Within the F2 generation, worms that show a non-dumpy phenotype and have green 
fluorescence along their body muscle were to singled. Since both dpy-5 and mod-5 are on 
chromosome I166,167, if the dumpy phenotype is not seen, this signifies that the worm is 
homozygous for the mod-5 mutation. The final step of this cross was to scan plates of F3 progeny 
for the non-dumpy and green phenotype in all the worms from the same F2 parent, showing that 
the F2 worm and its offspring are mod-5;dvIs100. This strain was named CEC215. 
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2.2.1.2.3 Generating tph-1;dvIs100 
To ensure that the reduced thrashing phenotype observed in untreated Aβ1-42 expressing 
worms (GMC101 – see results) was not the result of altered serotonin levels, worms deficient in 
serotonin synthesis, because of a mutation in tryptophan hydroxylase (TPH-1), were generated. 
Because serotonin itself has been directly implicated in normal C. elegans locomotion behaviour, 
this genotype served as a negative control to ensure that reduced locomotion in GMC101 worms 
was not an intrinsic product of Aβ1-42 influencing serotonin levels, but instead the consequence of 
progressive Aβ1-42 peptide accumulation in muscle cells. An intermediate dumpy marker strain 
(dpy-10), linked to tph-1 on chromosome II was used in a two-step strategy to produce tph-
1;dvIs100. The crossing scheme is indicated in Figures 5 and 6. 
 
2.2.2 Synchronization 
Worm cuticles are permeable to NaOH such that larvae and adult worms die if exposed to 
it. In contrast, egg shells provide an impenetrable barrier that protect embryos from caustic 
environments. By treating a mixed population on a plate with a bleaching solution and recovering 
viable eggs, a new developmentally synchronized population of hatching larvae representing a 12-
hour window of time (the time required to undergo embryogenesis) can be reconstituted. The 
protocol is shown below. 
a. Wash the worms and eggs off with Worm Bleaching Solution (WBS) and transfer 
into 1.5 mL Eppendorf tubes; this is the first step of the preparation for the paralysis 
assay or thrashing assay and as such is referred to as Day 1.  
b. Centrifuge at 10000 rpm for 2 minutes, then remove the supernatant.  
c. Resuspend the pelleted worms and eggs with 1000 µL M9 Buffer.  
d. Centrifuge the samples again at 10000 rpm for 2 minutes and repeat steps c and d two 
more times so that the eggs are rinsed three times.  
e. Resuspend the pellet in 500 µL of fresh M9 Buffer and pipette onto NGM plates 
without OP50. 
f. The following day wash the hatched L1 worms off the plate with 1.0 mL of M9 
Buffer, centrifuge at 5000 rpm for 2 minutes, remove most of the supernatant, and 
plate the worms onto a seeded NGM plate. 
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Figure 2.3: Cross scheme for generating dpy-10;dvIs100 worms. 
To determine whether serotonin played a role in the thrashing behaviour, worms that encode the 
sequence for Aβ1-42 and lack tryptophan hydroxylase activity were produced. Male GMC101 
worms were crossed with hermaphroditic CB128 worms overnight on mating plates. The CB128 
worms were then singled and removed once the eggs were laid. Within the F1 generation, if the 
cross occurred, all worms should be dpy-10 +/+ dvIs100, and appear non-dumpy, with possibly 
faint green fluorescence along the body muscle, if any. F1 worms were singled and left to self-
fertilize; from the F2 generation, worms showing the dumpy phenotype and green fluorescence 
along their body muscle were singled to score the F3 generation. Plates with all worms expressing 
the dumpy phenotype and green fluorescence were homozygous dpy-10;dvIs100. This strain was 
named CEC217. 
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Figure 2.4: Cross scheme for generating tph-1;dvIs100 worms. 
To complete the second portion of the cross, male MT15434 worms hermaphroditic CEC217 
worms were crossed overnight. The CEC217 worms were singled, left to lay eggs, then removed 
so only the F1 generation would remain. If the cross occurred, all worms should be heterozygous 
for tph-1+/+ dpy-10;dvIs100/ +, appearing non-dumpy and possibly with faint green fluorescence 
along the body muscle. These worms were singled and left to self-fertilize, then the F2 generation 
was scored for worms that showed a non-dumpy phenotype and had green fluorescence along their 
body muscle to single. Since both dpy-10 and tph-1 are on chromosome II166, if we do not see the 
dumpy phenotype, we can assume that the worm is homozygous for the tph-1 mutation. The final 
step of this cross was to scan plates of F3 progeny for the non-dumpy and green phenotype in all 
the worms from the same F2 parent, showing that the F2 worm and its offspring were homozygous 
tph-1;dvIs100. This strain was named CEC218. 
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2.2.3 Heat-killed Bacteria 
 Live bacteria, used as food for C. elegans cultures can metabolize Fluoxetine170. To control 
for the potential interference of bacteria-derived SSRI metabolites contributing to Aβ 
accumulation in worm tissues, heat-killed E. coli were used. The bacteria were killed using the 
following steps: 
a. Inoculate lysogeny broth (LB) with bacteria and incubated at 37ºC overnight. 
b. Centrifuge the LB and bacteria mixture in an Eppendorf Centrifuge 5804 at 4 500 
rpm for 10 minutes in 50 mL Falcon tubes until all the E. coli has formed a pellet at 
the bottom of the tubes.  
c. Remove the supernatant 
d. Resuspend the pelleted bacteria in 5 mL of fresh LB.  
e. Pipette 1 mL of this solution into 1.5 mL Eppendorf tubes and place into a VWR 
Analog Heatblock at 70ºC for 30 minutes.  
f. Collect the heat-killed E. coli in a 15 mL Falcon tube until required to seed the 
treatment plates. This protocol is based on the description by Ren and colleagues170. 
To ensure that the heated E. coli had been killed, three 15 mL Falcon tubes with 3 mL of 
LB were tested. One was not inoculated and used as a negative control to ensure that the LB itself 
had not been contaminated; one tube was inoculated with the E. coli before it was heated to be 
used as a positive control; and the last was inoculated with the heated bacteria. All are incubated 
at 37ºC overnight to test for growth. 
 
2.2.4 Paralysis assays 
As a simple visual readout to indirectly test the potential effect of SSRIs on the 
accumulation of Aβ in live C. elegans, populations of worms expressing dvIs100 (GMC101) with 
different drug treatments were analysed in different time-points for changes in the previously 
described Aβ-dependent, paralysis curve. In the context of GMC101, paralysis, defined as the 
absence of detectable core movement on a solid medium, is an induced phenotype resulting from 
the ectopic accumulation of a human peptide in muscle cells of these worms. The deposition of 
Aβ peptides in these cells is thought to lead to progressive paralysis and, ultimately, paralysis of 
the whole organism. Previously, other laboratories had characterized the rate of paralysis in 
GMC101 animals as a function of time as an experimental platform to screen for conserved genes 
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that influence Aβ toxicity171,172. Though not directly informative on neuronal Aβ toxicity, this 
assay was therefore a natural experimental entry point to functionally probe whether SSRI 
treatment could disturb the normal progression of Aβ accumulation significantly enough to 
influence a whole organism level response (movement).  
The following steps describe the assay: 
a. On day one, inoculate a flask with sterile LB media with OP50 and place it in a 
Thermo Scientific MaxQ 4000 shaker incubator overnight at 37ºC at 165 rpm; the 
drug will be administered by mixing it with the OP50. Synchronize the strains using 
the protocol above and prepare 35 mm NGM plates to use for the treatments later.  
b. On day two, once the eggs have hatched, move L1 worms by washing with 1000 µL 
M9 buffer onto NGM plates seeded with OP50. As well, seed the 35 mm plates with 
100 µL of OP50 or the OP50 + drug mixture composed of 1 µM or 10 μM Fluoxetine 
or nor-Fluoxetine diluted in dH2O. Once seeded, leave the plates on the bench (at 
20ºC) until the bacterial and drug lawn has dried, then move them into a 4ºC fridge to 
prevent desiccation. 
c. On day four the worms have reached the L4 stage. Pick 15 worms with a platinum 
wire onto each of the treatment plates. Twelve hours after the worms are picked onto 
the plates is the first time-point to score for paralysis.  
d. Score the worms at 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, and 42-hour time-points.  
Paralysis was assigned to animals that showed loss of movement in the central body region 
(region from head to tail) that prevented further foraging behaviour. Some remaining head and tail 
side-to-side swaying may still be displayed even in fully immobile GMC101 animals, as the 
paralysis only occurs throughout the body muscle cells. These worms were scored as paralyzed 
for the purpose of  this analysis171. To exclude dead animals from being scored as paralyzed, 
immobile worms were gently prodded with a platinum wire to check for the normal head backing 
response to touch stimuli. Only the worms that did show a retractile response were scored as 
paralyzed, while those that did not respond were discarded. 
 
2.2.5 Thrashing assays 
Because of the variability in measuring movement against a solid, high friction surface 
where varying levels of movement impairments are hard to distinguish, this paralysis assay is 
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prone to experimental biases, tends to overestimate or underestimate paralysis depending on the 
level of functional compromise, and is therefore best used as a qualitative indicator of a phenotypic 
trend. An alternative assay that measures number of thrashes over time on liquid can be used as a 
quantitative way to address minor movement impediments before full paralysis ensues. The assay 
is based on a worm being placed in a drop of M9 Buffer and the number of complete side-to-side 
lateral swimming movements in a specified amount of time recorded. Because the number of 
thrashes corresponds to muscle vigor, values can be assigned and compared against a standard 
genetic background (WT, etc.) or treatment. To prevent external factors, such as age, from 
influencing the analysis, thrashing behaviour was quantified in the same timeline and with the 
same drug regimes used for the paralysis assays (see above). One thrash was assigned to a single 
lateral bend of the body as the head and tail point towards the same side. Measurements were taken 
on day 5, either at hour 18 or 24, and one on day 6, at hour 42 or 36, respectively. Individually, 5 
worms were picked off each treatment plate in 5 µL of M9 Buffer on a glass slide and given 20 
seconds to acclimatize to the new media. Thrashing was manually counted for the following 30 
seconds using a Nikon SMZ 745 microscope.  
 
2.2.6 Maintaining cell lines 
2.2.6.1 HEK293, N2a, and HT22 
These cells were grown in DMEM + 10% FBS in a Thermo Scientific HERACell VIOS 
160i incubator at 5% CO2 and 37ºC. 
 
2.2.6.2 SH-SY5Y 
These cells were grown in DMEM/F12 + 10% FBS in a Thermo Scientific HERACell 
VIOS 160i incubator at 5% CO2 and 37ºC. 
 
2.2.7 Transfecting cells 
Cells were overexpressed with APP to study the effects of SSRIs on the accumulation of 
Aβ. Cell transfections were performed using the following protocol: 
a.  Split the cells so that by the day that they are harvested, they are at 90% confluency, 
requiring the transfection to be set up at 50-70% confluency, depending on the rate of 
growth of the cells.  
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b. Make a master-mix for each experiment to minimize any differences between plates, 
with enough for one extra plate included for any pipetting error. For each plate, 
include 900 µL OPTI-MEM reduced serum media and 9 µg of either pcDNA3.1 
vector, pcDNA3.1/APPWT, or pcDNA3.1/APPSwe/Ind per plate to make up the two 
Solution As. The plasmids were amplified using the Qiagen HiSpeed® Plasmid Maxi 
Kit. 
c. Solution B consists of 900 µL OPTI-MEM reduced serum media and 27 µL 
Lipofectamine Reagent per plate.  
d. Add Solution A and the appropriate amount of Solution B together and gently mix 
and allow them to incubate for 15 minutes.  
e. While incubating, aspirate off the media on the plates and rinse with 7.5 mL warm 
serum-free media, then also aspirate this off.  
f. After the incubation period has elapsed, 7.2 mL serum-free media per plate is added 
to each combined Solution A and B then gently mixed.  
g. Pipette 9.0 mL of the Solution A, Solution B, and serum-free mixture gently onto 
each plate of cells, according to the treatment they are to receive. 
h. Return the cells to the Thermo Scientific HERACell VIOS 160i incubator for 6 hours. 
i. After the 6 hours, supplement the media with 9.0 mL DMEM + 20% FBS and add in 
18 µL of Fluoxetine for a 10 µM treatment or 45 µL for a 25 µM treatment. Nothing 
extra is added for the 0 µM treatment, aside from the supplemental media. 
j. After 24 hours, remove the plates from the incubator and place them on ice to stop 
any additional metabolism. 
k. Collect the media in a 15 mL Falcon tube and centrifuge it to collect any cells that are 
not adhered to the plate. Remove the supernatant to a 50 mL Falcon tube to freeze the 
media in until ready to IP. 
l. Gently rinse cells with 6mL of cold 1x PBS, then aspirate the 1x PBS off. 
m. Pipette 3 mL TE to plates to detach cells. Allow them to sit for a few minutes.  
n. Use a P1000 micropipette to wash the cells off the plate with the TE and add it to the 
cells in the 15 mL tube. 
o. Rinse the rest of the cells off with 6 mL of cold DMEM + 10% FBS and add it to the 
15 mL tube with cells, then centrifuge for two minutes to pellet cells. 
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p. Discard the supernatant. 
q. Resuspend the cells with 500 µL of cold 1x PBS and move the cell solution into a 1.5 
mL microcentrifuge tube. 
r. Rinse the 15 mL tube with an additional 500 µL of cold 1x PBS to retrieve any cells 
left and add it to the same microcentrifuge tube 
s. Pellet the cells by centrifugation with 5 000 rcf for 2 minutes, then discard the 
supernatant. Store the cell pellet in a freezer until time to lyse. 
 
2.2.8 Cell lysis 
The cells were harvest from 15 cm diameter cell culture plates, described above and 
pelleted by centrifugation. The pellets were stored at -20°C until needed. During the cell lysis 
steps, cell pellet was kept on ice. The following steps were used to lyse the pellets: 
a. Make a 1x RIPA/1x PIC Buffer from frozen stock supplies of 10x RIPA and 100x 
PIC and dilute with millipore water.  
b. Resuspend the cell pellet in 600 µL of 1x RIPA/1x PIC Buffer and incubate on ice for 
30 minutes.  
c. Centrifuge the samples at 12 000 rcf for 10 minutes at 4ºC.  
d. Transfer the supernatant to a new tube. This is the soluble fraction that will be used 
throughout future tests. The remaining pellet comprises the insoluble fraction and is 
frozen for later uses.  
 
2.2.9 Sequential immunoprecipitation (IP) of the soluble fraction 
As APP is able to be cleaved into a multitude of different variants, a sequential IP was used 
to help isolate some of the larger populations of amyloid peptides after protein determination was 
completed using the Total Protein Kit, Micro Lowry, Peterson’s Modification. All IPs were set up 
in triplicate, with two sets containing 300 µg, one to use to test for Aβ using a urea gel and one to 
test for any interactions between SERT and Aβ using a 10% SDS-PAGE gel. The lysis protocol 
used allows proteins to remain in their typical conformation, also maintaining the integrity of 
interactions between proteins. Because of this, an antibody can be used to pull out Aβ then probing 
for SERT to detect any interactions. The third replica was set up with 100 µg of protein to look for 
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the levels of sAPPα using a 10% SDS-PAGE gel. The first step of the sequential IP uses a C-Term 
antibody to pull out full length APP, C99, C83, and AICD fragments. The following step uses 
6E10, which binds amino acids 1-17, and pulls out Aβ and sAPPα.  
The following steps were used to begin the C-Term IP: 
a. Add the volume of the soluble fraction necessary for 300 µg or 100 µg to 1x RIPA/1x 
PIC Buffer for a final volume of 400 µL.  
b. For the samples with 300 µg, add 4.5 µL of the C-Term antibody diluted 1 in 4 in 5% 
BSA in 1x RIPA/1x PIC Buffer and 60 µL of 50% slurry of Protein A sepharose 
beads. To the samples with 100 µg of protein, add 1.5 µL of the C-Term antibody 
diluted 1 in 4 in 5% BSA in 1x RIPA/1x PIC Buffer and 20 µL of 50% slurry of 
Protein A sepharose beads.  
c. Vortex and leave to rotate overnight at 4ºC.  
d. The following day centrifuge the samples at 5 000 rcf for 2 minutes at 4ºC.  
e. Transfer the supernatant into a new microcentrifuge tube for the 6E10 IP and store in 
the 4ºC fridge until it is set up.  
f. Wash the beads with 500 µL of HNTG buffer, vortex, and centrifuge at 5 000 rcf for 
2 minutes.  
g. Discard the supernatant and repeat step f twice, so that three washes have been 
completed 
h. For the final wash removal, use a 30-gauge needle to remove the remainder of the 
HNTG buffer off the beads 
i. Add 20 µL of 2x Laemmli buffer to the beads and vortex. Freeze the samples until 
they are run on gels. 
The 6E10 IP follows a very similar procedure as used for the C-Term IP. The supernatant 
from the 300 µg C-Term IP had 4.5 µL of 6E10 antibody and 60 µL of 50% slurry of Protein G 
sepharose beads added. The supernatant from the 100 µg IPs receive 1.5 µL 6E10 antibody and 20 
µL 50% slurry of Protein G sepharose beads. Vortex the samples and leave them to rotate overnight 
at 4ºC. The wash steps are the same as described above for the C-Term IP.  
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2.2.10 Immunoprecipitation from media 
To measure the levels of Aβ in the media, a 6E10 IP was performed using the following 
steps: 
a. Add 9.0 µL 6E10 antibody and 60 µL of 50% slurry of Protein G sepharose beads to 
the media.  
b. Vortex the tubes and put the samples on a rotator overnight at 4ºC.  
c. The following day centrifuge the samples at 5 000 rcf for 5 minutes, then transfer the 
supernatant to a new tube to save. 
d. Use 500 µL of HNTG buffer to resuspend the beads and transfer them to a 
microcentrifuge tube.  
e. Use an additional 500 µL of HNTG buffer to rinse the tube and add it to the same 
microcentrifuge tube and vortex. 
f. Centrifuge the samples at 5 000 rcf for 2 minutes then remove the supernatant. 
g. Repeat the washes with 1.0 mL two more times for a total of three washes. 
h. Use a 30-gauge needle to remove the remaining buffer from the beads. 
i. Add 20 µL of 2x LB to the samples and vortex. Freeze the samples until they are run 
later. 
 
2.2.11 Western Blotting 
2.2.11.1 Antibodies 
Full length APP was detected in cell lysate using a mouse anti-APP antibody, 22C11. This 
antibody binds to the N-terminus spanning amino acid residues 66 to 81 and can detect three forms 
of APP; immature at 110 kDa, sAPPα at 120 kDa, and the mature form at 130 kDa173. The 
immature APP species is N-glycosylated while the mature species of APP is N- and O-
glycosylated and has a sulfated tyrosyl residue, causing its molecular weight to be higher. 
The soluble N-terminal fragment of APP, i.e. sAPPα, was identified using the 22C11 
antibody. First cell lysates were immunodepleted with an antibody that binds to the C-terminus of 
APP. This removes full length APP and the C-terminal C99, C83, and AICD fragments by binding 
to amino acid residues 66-81. As sAPPα lacks the C-terminus epitope, this peptide remains in the 
supernatant. 
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As Aβ peptides also lack the C-terminus epitope, they also remain in the supernatant and 
can be immunoprecipitated using the mouse monoclonal 6E10 anti-Aβ antibody. 6E10 binds to 
the N-terminal spanning amino acid residues 1 to 17. 
SERT levels were detected in resolved cell lysates with a rabbit polyclonal anti-SERT 
antibody. SERT from Biorbyt binds to amino acid residues 411-490 of the human transporter. 
 The secondary used to detect all the mouse primary antibodies was anti-mouse in the 800 
infrared dye channel to be visualized with LICOR. The antibody is used at a dilution of 1:20 000. 
  The secondary used to detect rabbit antibodies was anti-rabbit in the 800 infrared dye 
channel, visualized using LI-COR. This antibody was used at a dilution of 1:20 000. 
 
2.2.11.2 Urea/SDS-PAGE Protocol 
Urea/SDS-PAGE gels are composed of three separate layers: the comb gel, stacking gel, 
and the resolving gel. Table 1 in Appendix A displays the constituents that the gels are composed 
of. The protocol to make and run these gels is as follows: 
a. Dissolve the urea in separation buffer and 40% acrylamide overnight in a 10 mL flask 
on a stir plate at RT. 
b. The following day add 10% SDS and gently mix.  
c. Add 10% APS, made fresh on the day the gel is cast, and TEMED in sequence with 
mixing in between. 
d. Pour 3900 µL of the resolving gel for each plate with 1.0 mm spacers, then pipette a 
thin layer of H2O saturated butanol on top to remove bubbles and make the top of the 
gel level. 
e. Once solidified, rinse off the butanol with dH2O and allow it to dry before the next 
layer is poured.  
f. Combine all components of the stacking gel and mix, then add the 10% APS and 
TEMED, with mixing between. Immediately pour 900 µL of the stacking gel above 
the resolving gel along with a layer of butanol. 
g. After the stacking gel has solidified, rinse the butanol off with dH2O. 
h. Combine the components for the comb gel, adding 10% APS and TEMED last with 
mixing between, and pour to the top of the plates and place the comb quickly after. 
i. Once completely solidified, rinse the plates with dH2O and gently remove the comb. 
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j. Set the unit up with the plates cast that day. Add 1X Cathodic Buffer (0.2 M Bicine + 
0.1 M NaOH + 0.25% SDS as final concentrations made from 32.6 g Bicine + 4 g 
NaOH + 2.5 g SDS in 1000 mL ddH2O) to the inner chamber and 1x Anodic buffer 
(2.0 M Tris + 0.5 M H2SO4 as final concentrations made from 242 g Tris + 27.8 mL 
H2SO4 in 1000 mL ddH2O) to the outer chamber. 
k. Load the appropriate volume of sample and Specter Low Range ladder, run the gels at 
15 mA per plate for roughly three hours.  
l. Once the gels have finished running, transfer in Transfer Buffer at 65 mA for two 
hours. 
m. Briefly move the membranes to dH2O, then boil in a petri dish with 100 mL of 1x 
PBS for 3 minutes. 
n. After boiling, block the membranes with 5% milk in 1x TBS for 1 hour. 
o. Wash the membranes three times for roughly 10 minutes each in 1x TBST to remove 
excess blocking solution. 
p.  Probe the membranes in the primary antibody overnight at 4ºC on a rocker. 
q. The following day wash the membranes three times for roughly 10 minutes each in 1x 
TBST. 
r. Probe the membranes in the appropriate secondary antibody at RT for 1 hour on a 
rocker. 
s. Wash the membranes three times for roughly 10 minutes each in 1x TBST then 
visualize using LI-COR.  
 
The samples, roughly 25 µL, were resolved alongside 5 µL of Specter Low Range Ladder. 
The type of gel and concentration of primary used to probe are described in the corresponding 
figure legend to the experiment run. 
 When visualizing with LI-COR, the settings used are an intensity of 10.0, quality of low, 
and resolution of 84nm using the 800 channel. 
 To save membranes for a later use, they are bagged in 1x TBS and stored at 4ºC. 
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2.2.11.3 SDS-PAGE 
 Western blots are composed of two layers: the stacking gel and the resolving gel. The 
components of the gels are displayed in Table 2 of Appendix A. The protocol to make and run 
these gels is as follows: 
a. Combine the components of the resolving gel and gently mix.  
b. Add 10% APS, made fresh on the day the gel is cast, and TEMED in sequence with 
mixing in between. 
c. Pour 4300 µL of the resolving gel for each plate with 1.0 mm spacers, then pipette a 
thin layer of H2O saturated butanol on top to remove bubbles and make the top of the 
gel level. 
d. Once solidified, rinse off the butanol with dH2O and allow it to dry before the next 
layer is poured.  
e. Combine all components of the stacking gel and mix, then add the 10% APS and 
TEMED, with mixing between. Immediately pour the stacking gel to the top of the 
plates and place the comb quickly after. 
f. Set the unit up with the solidified plates cast that day. Add 1X Running Buffer 
(25mM Tris HCl + 192 mM Glycine + 0.1% SDS as final concentrations made from 
30.3 g Tris Base + 144.0 g Glycine + 10 g SDS to a total volume of 1.0 L in dH2O, 
then diluted 1 in 10 with dH2O) to the inner and outer chambers.  
g. Load the appropriate volume of sample and PageRuler Prestained Protein ladder, run 
the gels at 50 V for 30 minutes then at 180 V for roughly another hour for 
completion.  
h. Once the gels have finished running, transfer in Transfer Buffer (25 mM Tris HCl + 
192 mM Glycerol + 3.75% SDS + 20% MeOH as final concentrations made from 12 
g Tris Base + 57.6 g Glycine + 150 mg SDS + 800 mL Methanol diluted to a volume 
of 4 L with dH2O) at 230mA for 90 minutes. 
i. Block the membranes with 5% milk in 1x TBS for 1 hour. 
j. Wash the membranes three times for roughly 10 minutes each in 1x TBST to remove 
excess blocking solution. 
k.  Probe the membranes in the primary antibody overnight at 4ºC on a rocker. 
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l. The following day wash the membranes three times for roughly 10 minutes each in 1x 
TBST. 
m. Probe the membranes in the appropriate secondary antibody at RT for 1 hour on a 
rocker. 
n. Wash the membranes three times for roughly 10 minutes each in 1x TBST then 
visualize using LI-COR.  
 
The samples, roughly 25 µL, were resolved alongside 5 µL of PageRuler Prestained Protein 
Ladder. The type of gel and concentration of primary used to probe are described in the 
corresponding figure legend to the experiment run. 
 As with the urea/SDS-PAGE gels, the regular WBs were also visualized with LI-COR, at 
an intensity of 10.0, quality of low, and resolution of 84nm using the 800 channel. 
 To save membranes for a later use, they are bagged in 1x TBS and stored at 4ºC. 
 
2.2.12 Statistical analyses using SPSS software 
2.2.12.1 Kaplan-Meier Test 
As the data points from the paralysis assays can be statistically analyzed similarly to 
survival curves, the Kaplan Meier test was used to determine whether the type of drug treatment 
altered the rate of paralysis associated with Aβ accumulation in control animals (CL2122), Aβ3-42-
producing worms (CL2120), and Aβ1-42-producing worms (GMC101). If a difference was seen 
between the vehicle, 1µM and 10µM, additional Kaplan-Meier tests were used to compare two 
treatments at a time using a corrected α of 0.0167. 
 
2.2.12.2 Kruskal Wallis and Mann Whitney U Tests 
The data collected from the thrashing assays was not normally distributed (forming a bell-
shaped, symmetrical curve around the mean), thus a Kruskal Wallis and subsequent Mann Whitney 
U post-hoc tests were used to determine whether each treatment (vehicle, 1µM Fluoxetine or nor-
Fluoxetine, or 10 µM Fluoxetine or nor-Fluoxetine) had different effects on the thrashing 
behaviour of C. elegans. Mann Whitney U tests were utilized to analyze the groups pairwise using 
a corrected value of α = 0.0125 as each set of data was compared four times. 
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3 Results 
3.1 Fluoxetine does not influence Aβ-associated paralysis in C. elegans. 
The effects of the SSRI, Fluoxetine, on modulating Aβ accumulation was initially 
investigated using a paralysis paradigm. Increasing Aβ production in muscle cells of transgenic C. 
elegans (CL2120 and GMC101) results in a progressive paralysis phenotype155,165. Measurement 
of the percentage of paralyzed animals as a function of time can therefore be a useful, albeit 
indirect, assessment of Aβ accumulation. When plotted on a curve, these rates provide a dynamic 
picture of Aβ toxicity. If Fluoxetine can alter the rate of Aβ production or accumulation in these 
worms, it follows that paralysis rates will likely reflect this effect. For instance, a precipitated spike 
in paralysis as indicated by reaching 50% of paralyzed (50p) worms at an earlier time-point than 
that observed for untreated controls would suggest that Fluoxetine potentiates Aβ accumulation. 
Conversely, a delay in reaching 50p on a paralysis curve would be consistent with a protective role 
for this drug. 
Using this experimental approach, worms treated with either a vehicle or one of two 
concentrations of Fluoxetine were scored for complete paralysis, i.e. when no central body 
movement is detectable. In these assays, GMC101 (Aβ1-42) and CL2120 (Aβ3-42) populations 
displayed a profile of increasing paralysis overtime that agrees with previous reports155 (Figure 7). 
As indicated in the paralysis curves in Figure 7A and 7C and demonstrated by calculating the 
relevant P values in Table 1 in Appendix B, Fluoxetine treatment did not significantly skew the 
paralysis response of worms expressing Aβ peptides in muscle tissue.  
A factor potentially interfering with these results relates to the metabolism of Fluoxetine 
to nor-Fluoxetine by live E. coli. The direct role of nor-Fluoxetine in the context of the paralysis 
assay must therefore be separately addressed (see Section 3.2, below) as it possibly contributes 
(acts in synergy with Fluoxetine) or masks (competes for binding with Fluoxetine) Aβ 
accumulation in these backgrounds. Nor-Fluoxetine is also the major Fluoxetine metabolite in 
humans, suggesting that bacterially-processed Fluoxetine could be altering the molar ratio of these 
SSRIs compounds on plates and potentially altering the behavioural responses observed in these 
assays174. To avoid this potential confound, Fluoxetine was added to bacterial lawns made of dead 
E. coli. In these plates, bacterial contribution to nor-Fluoxetine concentrations at the expense of 
Fluoxetine inputs should not be a factor. 
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Interestingly, when comparing the motility responses of worms exposed to Fluoxetine on 
live versus dead E. coli lawns, noticeable differences in the rate of paralysis could be observed 
(Figure 7). When the drug was delivered on live E. coli food the 50p time-point was reached at 32 
hours in vehicle-treated Aβ3-42-producing animals (CL2120) as compared to 34 hours in Fluoxetine 
treated CL2120 worms, where the vehicle treated worms continue to worsen until the final time-
point of 42 hours while the Fluoxetine treated plateaued (Figure 7A; P = 0.241), indicating a 
potential protective effect of Fluoxetine on Aβ accumulation. However, the same treatments when 
repeated on a heat-killed bacteria substrate, resulted in a premature paralysis of Fluoxetine-treated 
CL2120 worms when compared to control (Figure 7C; P = 0.355) suggesting that the delay in 
paralysis establishment of the genetically identical worms growing on live, metabolizing bacteria 
plates may be accounted by a reduced Fluoxetine intake, higher nor-Fluoxetine concentrations, the 
presence of another Fluoxetine metabolite or several of these factors in combination. It is important 
to note that as the data were not statistically different no conclusion can be made. 
With respect to the Aβ1-42-producing worms (GMC101), and consistent with previous 
reports155 implicating more robust accumulation of Aβ1-42 in AD, paralysis rates were generally 
higher in early time-points as compared to CL2120 worms (comparing Figure 7A to 7B and 7C to 
7D). However, the perceived effect of bacteria substrates insofar as modulating paralysis rates 
observed for CL2120 worms was not reproducible in GMC101 animals; whether Fluoxetine was 
delivered in live or dead bacteria did not seem to alter the overall paralysis response as compared 
to untreated Aβ1-42 expressing worms (comparing Figure 7B and 7D). These results could represent 
intrinsic differences between the Aβ peptides, though the lack of statistical significance between 
these datasets more likely reflect sample specific variations. In addition, a concentration-dependent 
effect could not be found between the 1 µM and 10 µM Fluoxetine treatments (Table 1 of Appendix 
B). 
 
3.2 Nor-Fluoxetine does not influence Aβ-associated paralysis in C. elegans. 
Nor-Fluoxetine, a by-product of Fluoxetine metabolism, has a much longer half-life than 
its parent compound147. As nor-Fluoxetine has a slower turnover rate in the body, it could have 
clinically relevant roles in explaining outlasting or delayed effect of SSRI treatment, particularly 
with respect to Aβ toxicity in patients with a chronic, lifelong use of SSRIs. To dissect the 
consequence of nor-Fluoxetine exposure to Aβ accumulation in C. elegans, the paralysis assay 
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protocol performed for Fluoxetine (see Section 3.1) were repeated using pure nor-Fluoxetine added 
to plates with live and dead bacteria (Figure 8). 
Despite the lack of solid evidence in support of a significant effect of Fluoxetine and nor-
Fluoxetine in paralysis rates, some interesting observations suggest that these two drugs may have 
an additive effect. Treating GMC101 worms with different concentrations of Fluoxetine yielded 
similar 50p time-points, occurring at around 32-34 hours (Figure 7). When GMC101 worms 
growing in live E. coli were treated with nor-Fluoxetine these populations reached 50p 2 to 4 hours 
later at 36 hours, pointing to differences in the response to these related SSRIs. Interestingly, in 
GMC101 populations exposed to 10 µM nor-Fluoxetine on dead bacterial lawns where no source 
of Fluoxetine existed, 50p was reached much sooner at 32 hours than in the treatment with 1 µM 
Fluoxetine (50p = 42 hours) and no treatment control (50p = 42 hours) (Figure 8D). This treatment 
thus supports a dose-dependent role of nor-Fluoxetine in driving progressively more accumulation 
in Aβ1-42 expressing worms when compared to Fluoxetine. In this interpretation, providing pure 
nor-Fluoxetine to worms from the start of the treatment bypasses the slower processing of 
Fluoxetine metabolism (by bacteria and/or worms) and nor-Fluoxetine accumulation (in worms) 
presumably speeding up the process of Aβ accumulation in muscle. Though an interesting 
possibility, these conclusions are currently not statistically supported (P = 0.135). Further work to 
reproduce these results is necessary. 
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Figure 3.1: Fluoxetine does not influence Aβ-associated paralysis in Aβ3-42 (CL2120) and 
Aβ1-42 (GMC101) worms. 
The control strain used for the paralysis assays is CL2122, which does not express and accumulate 
any form of Aβ. (A) CL2120 worms treated with live E. coli and Fluoxetine. (B) GMC101 worms 
treated with live E. coli and Fluoxetine. (C) CL2120 worms treated with dead E. coli and 
Fluoxetine. (D) GMC101 worms treated with dead E. coli and nor-Fluoxetine. All four panels 
show a range of paralysis trends, none of which were found to be significantly different from the 
vehicle treatment or the control strain. 
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Figure 3.2: Nor-Fluoxetine does not influence Aβ-associated paralysis in Aβ3-42 (CL2120) 
and Aβ1-42 (GMC101) worms. 
The control strain used for the paralysis assays is CL2122, which does not express and accumulate 
any form of Aβ.  Panel (E) displays CL2120 worms treated with live E. coli and nor-Fluoxetine. 
(F) GMC101 worms treated with live E. coli and nor-Fluoxetine. (G) CL2120 worms treated with 
dead E. coli and nor-Fluoxetine. (H) GMC101 worms treated with dead E. coli and nor-Fluoxetine. 
All paralysis assays did not show any statistically significant difference between the two nor-
Fluoxetine treatments and the vehicle treatment or with the control strain. 
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3.3 Thrashing behaviour is a better indicator of Aβ-induced paralysis in C. elegans. 
 Although the conclusion from the paralysis assays presented in Sections 3.1 and 3.2 did 
not support a role for Fluoxetine and nor-Fluoxetine in enhancing the Aβ-dependent paralysis 
phenotype in C. elegans, technical drawbacks of the assay have to be considered. The all-or-
nothing assessment for paralyzed versus non-paralyzed phenotypic outcomes as proxy for muscle 
function does not capture slighter, more gradual loss of movement that likely occurs as the cell’s 
capacity to process newly synthesized Aβ peptide is overcome. In this restricted scenario, the 
potential physiologically significant effects of SSRIs in C. elegans motility would not be 
accounted for if the time of paralytic onset was not ultimately affected. Likewise, because paralysis 
may not necessarily imply an endpoint in muscle function but simply a compounded effect beyond 
a threshold in which the remaining muscle activity is unable to propel movement, the assay equally 
ignores further muscle deterioration that could occur after the onset of paralysis. This assay is 
therefore blind to the continuum of possible physiological opportunities for Aβ regulation before 
and after the onset of complete paralysis and biased towards underestimating movement 
deterioration before paralysis while discarding the effects on left-over muscle activity after worms 
became immobile on the solid media. It is possible that SSRI-mediated modulation of Aβ 
accumulation does occur and is physiologically relevant but cannot be captured by the paralysis 
assay as it has been applied here. This can also be said about the thrashing assay, however, since 
quantifying thrashing is more sensitive to smaller differences in paralysis rate to be detected in the 
liquid media, and not just scored as paralyzed or not, it does offer a better alternative experiment 
to use. 
 To overcome the limitations of the paralysis assay and introduce a better quantitative 
assessment of the state of muscular function in Aβ expressing worms, thrashing assays were used. 
This assay consists of placing worms in liquid and scoring the frequency of lateral swimming. 
Reduced thrashing correlates with natural tissue deterioration in aging animals and has been 
extensively used as an index to evaluate the effects of new mutations and drugs on muscle and 
neuronal function175. Because these movements occur in a low resistant media, milder 
compromises in muscle function can be detected and quantified. In addition, worms perceived as 
paralyzed on agar plates can display residual movement observed as reduced thrashing rates in 
liquid, allowing for further characterization. Thus, thrashing quantification could, in principle, 
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resolve the issues of under- and overestimations of the consequences of Aβ accumulation in the 
paralysis assay used above.  
 As proof of concept to the suitability of using the thrashing assay for measuring Aβ-
induced paralysis, the range of thrashing rates for Aβ expressing worms (CL2120 and GMC101) 
treated with vehicle alone were initially determined (Figure 9 and 10). As reported previously, and 
in contrast to the results from the paralysis assay, Aβ3-42 worms do not show the same Aβ toxicity 
as seen with Aβ1-42 peptides (observed as a reduction in thrashing throughout the time-points 
tested) when compared with transgenic control worms that do not produce Aβ peptides (CL2122; 
Figure 7), consistent with the lower Aβ accumulate potential expected in these worms155. The 
difference seen within this strain between the two assays could be from the subjectivity of the 
paralysis assay or due to overestimation of paralysis caused by the added resistance of the solid 
media that the worms were scored on. In this context, and assuming SSRIs do influence thrashing 
behaviour through the regulation of Aβ accumulation, no significant effect on thrashing would be 
anticipated in treatments with Fluoxetine or nor-Fluoxetine. Indeed, culturing CL2120 in dead 
bacteria substrates containing these drugs does not significantly alter the range of thrashing rates 
(Figure 9; 0.141 ≤ P ≤ 0.638, Tables 3 and 6 in Appendix B). In contrast, Aβ1-42 worms have been 
shown to accumulate Aβ and paralyze as a result155. Consistent with these results, GMC101 worms 
(Aβ1-42) displayed a dramatic reduction in thrashing rates as compared to control animals (CL2122) 
in all time-points (Figure 10). Importantly, the compromise in muscle function, evidenced by 
reduced thrashing in Aβ1-42 worms, is progressively and significantly worsened in later time-points 
(comparing vehicle treated GMC101 datasets in Figure 10A and 10D; P < 0.001) demonstrating a 
dose-dependent effect of Aβ in the reduction of thrashing behaviour. Together, the results with 
vehicle treated CL2120 (Figure 9) and GMC101 (Figure 10) worms reveal in more detail the 
dynamics of paralysis derived from Aβ production and accumulation in muscle cells and validates 
the use of this experimental approach to re-test a role of SSRIs in these processes. 
 
3.4 Fluoxetine and nor-Fluoxetine exacerbate the reduction in thrashing in Aβ1-42-expressing 
worms. 
 To investigate whether SSRIs could disturb the normal kinetics of paralysis observed in 
Aβ1-42 worms, Fluoxetine and nor-Fluoxetine were added to dead bacteria and fed to GMC101 
worms. The thrashing behaviour of these worms was recorded at different time-points of adult life, 
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all chosen before complete paralysis transpires (reported previously to occur by 48 hours after 
being shifted to 25°C155) and compared to the response of control animals that did not express any 
Aβ peptide (CL2122). As observed in Figure 10, treatment with SSRIs leads to a substantial 
shortening of the time in which clear effects on movements can be detected in GMC101 worms, 
with animals showing a detectable reduction in thrashing behaviour already at 18 hours (Figure 
10A), at a time when no overt paralysis was observed in the paralysis assay (see Figure 7D). This 
finding supports the limitations of the paralysis assay insofar as assessing pre-paralysis 
compromise in thrashing of Aβ expressing worms, as suggested above. While treatment with 
Fluoxetine and nor-Fluoxetine resulted in a significant reduction in thrashing rates relative to 
control worms in all time-points tested, for the most part and with the exception of the 18 hour 
time-point (Figure 10A, Tables 4 and 7 in Appendix B), these effects were not dose-dependent 
(Figure 10B, 10C, and 10D). One possible explanation for these results considers that the only two 
doses tested (1 µM and 10 µM) may not cover the necessary range to induce detectable variation 
given the limited resolution of the paralysis assay. A final assessment of whether increasing 
Fluoxetine concentrations can impact protein aggregate loads in these cells should be performed 
by testing Aβ1-42-expressing worm lysates using Western Blots (WBs). These animals have been 
collected, but not processed at this time. Finally, comparisons between Fluoxetine and nor-
Fluoxetine-induced reduction in thrashing failed to reveal any significant differences. It appears 
that both compounds have a similar bioactive role in limiting movement presumably because of 
increased Aβ accumulation or oligomerization in muscle cells. Considering the shared chemical 
properties of these compounds, it is likely that both act on the same target to regulate Aβ 
expression, accumulation, or processing. Under the hypothesis of this thesis, this mechanism could 
involve co-opting the serotonin transport system (see below). However, it is also possible that 
these SSRIs act synergistically in different pathways. Controlled assays providing different molar 
ratios of Fluoxetine/nor-Fluoxetine to Aβ-expressing worms in thrashing assays would be 
important to dissect possible functional interaction of these drugs, an important and clinically 
relevant aspect of this analysis considering the co-existence of these molecules in patient’s brains.  
Overall, the results presented in this section support a role of SSRIs as potentiators of Aβ-
mediated toxicity in a transgenic model organism and point to important limitations of using the 
paralysis assay on solid surfaces for quantitative measurements of Aβ-driven paralysis. In line with 
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these findings, thrashing counts on animals grown on heat-killed E. coli were used henceforth to 
investigate the downstream effectors of SSRIs in worms. 
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Figure 3.3: Fluoxetine or nor-Fluoxetine do not influence thrashing in Aβ3-42-expressing 
worms. 
The data on the left side of the graphs represent worms treated with Fluoxetine and that on the 
right side were treated with nor-Fluoxetine and the error bars represent the 95% confidence 
interval. The “Control” data is collected for worms that do not produce Aβ (CL2122). Each strain 
and treatment combination represent the thrashing of ≤ 60 worms. Panel (A) represents the 
thrashing data collected after 18 hours of treatment, (B) is the data after 24 hours of treatment, (C) 
shows the data after 36 hours of treatment, and (D) is the thrashing data after 42 hours of treatment. 
At all time-points, Fluoxetine and nor-Fluoxetine treatment did not cause a significant difference 
in thrashing compared to the vehicle treatment in CL2120 (Aβ3-42) worms. The vehicle used in the 
thrashing assays was dead E. coli. 
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Figure 3.4: Fluoxetine and nor-Fluoxetine exacerbate the reduction in thrashing in Aβ1-42-
expressing worms. 
The data presented on the left side of the graphs are worms treated with Fluoxetine and the right 
side are those treated with nor-Fluoxetine and the error bars represent the 95% confidence interval. 
The data presented in Figure 9 are from worms treated and tested at the same time as the data 
displayed in this figure, with the “Control” (CL2122) data being from the same worms. Each strain 
and treatment combination represent the thrashing of ≤ 60 worms. Panel (A) represents the 
thrashing data collected after 18 hours of treatment, (B) is the data after 24 hours of treatment, (C) 
shows the data after 36 hours of treatment, and (D) is the thrashing data after 42 hours of treatment. 
The vehicle used in the thrashing assays was dead E. coli. After 24, 36, and 42 hours, a statistically 
significant difference is seen between the GMC101 (Aβ1-42) worms treated with the vehicle and 
10μM of Fluoxetine or nor-Fluoxetine. At the same time-points as above there is also a difference 
between the vehicle and 1μM of Fluoxetine and nor-Fluoxetine, except at 36 hours. However, there 
are also no differences found between the 1μM and 10μM treatments after 18 hours. One asterisk 
denotes 0.0167 > P > 0.001, two asterisks represent P = 0.001, and three asterisks show a 
significance level of P < 0.001. 
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3.5 SERT/MOD-5 is required for Fluoxetine/nor-Fluoxetine-dependent exacerbation of 
thrashing reduction in Aβ expressing worms.  
SSRIs promote serotonergic signalling by inhibiting postsynaptic serotonin uptake from 
synaptic clefts/neuromuscular junctions through binding to SERT, the ionotropic serotonin 
transporter on the membrane of neurons. Moreover, hypersensitivity to exogenous serotonin can 
lead to paralysis in worms through regulation of acetylcholine release in synapses. Deregulation 
of endogenous serotonin transport induced by SSRI treatment alone, however, cannot explain the 
reduced thrashing behaviour observed in GMC101 worms, since this effect required Aβ expression 
(see the unaffected thrashing behaviour of CL2122 worms treated with SSRIs in Figure 9 and 10). 
Alternatively, SERT has been proposed to bind and export other substrates, particularly α-
synuclein163, supporting a role of this transporter on diminishing the load of neurotoxic peptides. 
In this scenario, impairment of SERT-mediated transport using SSRIs may hinder the cell’s ability 
to remove Aβ peptides resulting in the formation of Aβ accumulates and, in the worm model, 
exacerbating the reduction in thrashing behaviour. 
Using clinically relevant drugs to treat the worms not only allows for translational 
relevance of these data, but, because of known pharmacology of these drugs, we can assume that 
they are acting on the worm analogue of SERT, MOD-5. However, there is always the possibility 
that these drugs, or any other drug, is eliciting an effect that is “off-target”, i.e. not acting through 
its expected target and mechanism. To test the possibility that SERT/MOD-5 mediates the 
sensitivity to Fluoxetine and nor-Fluoxetine in the context of muscle function in GMC101 worms, 
animals expressing Aβ1-42 (dvIs100) in a null mod-5 background (n3314) were generated. MOD-
5, the C. elegans SERT homolog, is expressed in motor neurons and is required for synaptic 
inhibition at neuromuscular junctions176. Importantly, MOD-5 has also been demonstrated to be a 
target of Fluoxetine in worms167. Thus MOD-5 appears to be present in the right place and have 
chemical affinity for SSRI ligands, both of which are requirements if this transporter is indeed 
behind the enhanced thrashing reduction observed in GMC101 worms. This theory is supported 
by evidence from Kullyev and colleagues where they showed that serotonin could not be detected 
in neurons with serotonin transporters in worms treated with Fluoxetine177.  If Fluoxetine and nor-
Fluoxetine act by antagonizing MOD-5-dependent Aβ export in these cells, genetic depletion of 
mod-5 should replicate the phenotypes triggered by the pharmacological inhibition of this 
transporter using SSRIs, as characterized above for GMC101 worms. Indeed, in the absence of 
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SSRI treatment, depleting mod-5 in Aβ1-42 (CEC215) using a null mutation (n3314) resulted in 
statistically significant reduction in thrashing behaviour compared to GMC101 animals at all four 
time-points tested (P < 0.001, Table 8 of Appendix B), suggesting that lack of MOD-5 activity is 
sufficient for the exacerbated reduction in thrashing observed upon SSRI treatment (Figure 11). 
As confirmed throughout these assays, the reduction in thrashing requires the dvIs100 (Aβ1-42) 
transgene expressing in muscle, such that mod-5 mutants alone are expectedly wildtype insofar as 
thrashing behaviour (Figure 11). Transporter as well as ligand are thus necessary to yield the 
paralysis phenotype. Presumably, binding of Fluoxetine and/or nor-Fluoxetine to MOD-5 in Aβ1-
42 (GMC101) worms to saturation levels could inactivate the transporter, leading to a comparable 
MOD-5 depleted phenotype that is achieved in an actual mod-5 mutant. It follows that the 
reduction in thrashing behaviour observed in untreated mod-5;Aβ1-42 (CEC215) worms (Figure 11) 
should not only be significantly more robust than in Aβ1-42 (GMC101) animals but also similar to 
the rates observed in Aβ1-42 worms treated with Fluoxetine and/or nor-Fluoxetine (Figures 9 and 
10). When directly compared, CEC215 worms do not show a statistically significant difference in 
thrashing behaviour (P ≥ 0.092), supporting the above hypothesis. 
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Figure 3.5: A non-functional MOD-5 exacerbates the reduction in thrashing in Aβ3-42-
expressing worms. 
Sixty worms of each strain were scored at each time-point in a thrashing assay to study the role of 
the serotonin transporter in the paralysis phenotype. The “Control” data is collected for worms that 
do not produce Aβ (CL2122). Panel (A) represents the thrashing data collected after 18 hours of 
treatment, (B) is the data after 24 hours of treatment, (C) shows the data after 36 hours of treatment, 
and (D) is the thrashing data after 42 hours of treatment. Three asterisks show a significance level 
of P < 0.001. 
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3.6 Serotonin is dispensable for MOD-5/SSRI-mediated regulation of Aβ-induced paralysis. 
 SSRIs were developed to increase the availability of serotonin, but there is always the 
possibility that a phenotype seen could be serotonin-independent and, indeed, serotonin-
independent functions of SSRIs have been reported in worms. For instance, while serotonin is 
required for SSRI-induced hyperenhanced slowing response, mod-5 mutants exposed to high 
concentrations (2.9 mM) of Fluoxetine display contraction of nose muscles followed by paralysis, 
suggesting that these compounds have alternative targets aside from the canonical serotonin 
transporter167. Conceivably, serotonin displacement to the cleft in mod-5;Aβ1-42 mutants could in 
itself impact intracellular Aβ loads indirectly. If serotonin is at all involved in Aβ toxicity observed 
in Aβ1-42 worms, for instance, the reduced thrashing phenotype in these animals should be 
suppressed or heightened by genetically eliminating serotonin signalling in the neuromuscular 
junction. This hypothesis was tested by producing a tph-1;Aβ1-42 (CEC218) that is impaired in 
serotonin production, but has normal MOD-5 mediated transport. As indicated in Figure 12, tph-
1(mg280) mutants showed a range of thrashing responses significantly different than the control 
CL2122 worms that do not express Aβ peptides at all time-points except 18 hours (P ≤ 0.006, 
Table 9 in Appendix B). Although this contradicts a previous report that swimming behaviour is 
not affected by impairment in serotonin production (tph-1) or transport (mod-5)178, when looking 
at the distribution of the data points the difference observed appears to be between the range of the 
two data sets, with worms showing both more and less thrashing behaviour than the controls, and 
the 95% confidence intervals overlap each other at all time-points except at 42 hours (Figure 12; 
P < 0.001). When tph-1 is introduced in Aβ1-42 expressing worms, however, a pattern of thrashing 
rates consistent with that observed for Aβ1-42 (GMC101) worms is present in all four time-points 
tested (Figure 12; 0.021 ≤ P ≤ 0.594, Table 9 in Appendix B). These results suggest that the 
absence of endogenous serotonin delivered to the neuromuscular junction by motor neurons does 
not disrupt the kinetics of Aβ accumulation in muscle cells and supports the conclusion that 
serotonin-independent roles of MOD-5, presumably exacerbated by SSRI treatment, mediate Aβ 
toxicity in this model. 
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Figure 3.6: A non-functional TPH-1 does not alter the reduction in thrashing in Aβ3-42-
expressing worms. 
The thrashing behaviour was compared to determine whether any changes in the availability of 
serotonin would influence thrashing behaviour. Sixty worms of each strain were tested. The 
“Control” data is collected for worms that do not produce Aβ (CL2122). Panel (A) represents the 
thrashing data collected after 18 hours of treatment, (B) is the data after 24 hours of treatment, (C) 
shows the data after 36 hours of treatment, and (D) is the thrashing data after 42 hours of treatment. 
No significant difference was seen between GMC101 and tph-1;Aβ1-42 (CEC218) worms at any 
time-point. Three asterisks show a significance level of P < 0.001. 
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3.7 The effects of Fluoxetine and nor-Fluoxetine on Aβ clearance through the mammalian 
serotonin transporter are inconclusive. 
 Confirmation of the role of MOD-5 in the Aβ-dependent paralysis phenotype was 
supported strongly by the C. elegans studies described above. The next challenge was to 
investigate the hypothesis that Aβ is able to be exported through SERT/MOD-5, thus SSRI 
treatment prevents its clearance. Although C. elegans provided a useful model to test the effects 
of Fluoxetine and nor-Fluoxetine on Aβ in a whole organism, to validate the involvement of SERT 
in Aβ transportation from the cell, mammalian cell culture was used. Cell culture provided a 
simpler and very controlled cellular model to display Aβ traffic. This allowed for a convenient 
model to compare Aβ levels within the cells to those presumably transported out into the culture 
media. It was hypothesized that if the SSRIs did prevent the movement of Aβ from the cell, it 
should be present more so within the cell; however, if it was still able to be cleared, the peptide 
should be observed within the culture media. In addition, mammalian cell culture allowed for an 
ideal method to model this movement within neuronal-like cells, as the C. elegans strains tested 
have Aβ accumulating within muscle cells. Preliminary data was produced in the Mousseau 
laboratory with HT22 mouse hippocampal cells. This initial test was performed to detect any 
effects of a range of Fluoxetine concentrations on the location of Aβ, whether within the cells or 
having been transported to the culture media. Increasing levels of Fluoxetine showed Aβ within 
the cell, while the lower concentrations had Aβ detection within the media (Figure 13). To further 
these studies, confirmation that HT22 was an appropriate cell line to test the effects of Fluoxetine 
on the accumulation of Aβ and where it localizes needed to be determined. The cell line to be used 
needed to have reasonable levels of SERT and the machinery to cleave APP to Aβ. HEK293 and 
HT22 cells displayed the greatest levels of SERT (Figure 14).  
HT22 and HEK293 were chosen to study going forward since the preliminary results were 
completed in HT22 and HEK293 had the most distinct SERT band present (Figure 14). Both 
strains were transfected with an empty pcDNA3.1 vector, the vector containing human APPWT, or 
the vector containing human APPSwe/Ind (Swedish-Indiana allele of APP) and treated with the 
vehicle, 10µM Fluoxetine, or 25µM Fluoxetine. The transfection was confirmed using WBs with 
the hypothesis that the samples transfected with the APP would show higher levels of this protein. 
Figure 15 displays that the cells transfected with APPWT and APPSwe/Ind contain more APP than the 
cells transfected with the empty vector in both HEK293 and HT22 cell lines. 
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Figure 3.7: Increasing Fluoxetine concentrations influence the location of Aβ in the culture 
media and in lysates in HT22 cells (unpublished data, Pennington and Mousseau, 2012). 
IPs and urea WBs were used to compare the presence of Aβ in cells and their corresponding culture 
media after increasing concentrations of Fluoxetine treatment. Aβ levels can be seen to decrease 
in the media with increased Fluoxetine treatment and is detected within the soluble fraction by the 
highest concentration. Membranes were probed with 1:1000 6E10 in 5% BSA in 1xTBST. 
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Figure 3.8: SERT expression is stronger in HT22 and HEK293 cell lines. 
Cell pellets were lysed and tested with a 10% Western blot for SERT expression. SERT appears 
to be present within some of the cell lines tested but is most clear within HT22 and HEK293 cell 
lines. The membranes were probed with 1:500 ST24A5 in 5% BSA in 1xTBST. 
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Figure 3.9: Overexpression of APP in HEK293 and HT22 cells is observed in all samples 
except those transfected with an empty vector, confirming a successful transfection. 
Cells were transfected with either an empty pcDNA3.1 vector, or one containing APPWT or 
APPSWE/IND and were treated with a vehicle, 10µM of Fluoxetine or 25µM Fluoxetine. Increased 
APP levels can be seen in all cell samples transfected with APP. Western blotting with 10% gels 
were used to test the samples and the membranes were probed with 1:1000 22C11 in 5% BSA in 
1xTBST. 
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 Once confirmed that the transfection was successful, IPs and WBs were used to concentrate 
and detect Aβ, whether in the soluble fraction (the supernatant after lysing the cell pellets) or within 
the culture media. For the soluble fraction of the cell sample, a sequential IP was used to remove 
specific fragments of APP; after C-TERM removed sAPPα, C99, and C83, the 6E10 antibody was 
used to isolate peptides containing amino acids 1-17 on the N-terminal of Aβ. WBs were then used 
to view whether Aβ was present within the soluble fraction of the HEK293 cells and the media 
(Figure 16). No amyloid variants around 10 kDa were detected in any of the treated cell samples. 
In contrast, the culture media from the samples that were transfected with APPWT and APPSwe/Ind 
did contain Aβ around 10 kDa. No difference can be seen between the Fluoxetine treatments, but 
the media from cells transfected with APPSwe/Ind do show a greater amount of Aβ (Figure 16). 
Similar methods were completed in HT22 cells and culture media (Figure 17); WBs with the 
soluble fraction and media samples of the HT22 cells show that Aβ was not able to be detected in 
either the soluble sample or within the media (Figure 17). 
 The hypothesis described above is based on the idea that Aβ is able to be transported 
through SERT. To determine if any metabolite of APP is associating with SERT, the sequential IP 
described above was used to pull out sAPPα, C99, and C83, then Aβ, followed by probing the 
membranes to detect SERT. A sample of the soluble fraction was also tested to look for initial 
levels of SERT within the HEK293 and HT22 cells. Any physical interaction between sAPPα, 
C99, or C83 and SERT and if any association is present between Aβ and SERT in HEK293 cells 
is shown in Figure 18. In HEK293, it is not distinctly evident whether any of the four APP 
metabolites are physically associated with SERT. A very faint band can be seen in some C-TERM 
IP samples around 55 kDa, but no SERT detection is evident in the 6E10 IP, suggesting that Aβ is 
not bound to SERT in these samples. The first panel in Figure 18 shows that SERT is present 
within HEK293, confirming that the lack of interaction is not the result of the cells not containing 
SERT. The same procedures were completed with HT22 cells and are shown in Figure 19; SERT 
does appear to have some interaction with sAPPα, C99, or C83, but not with Aβ. The top panel 
faintly shows that SERT can be found within the cell samples, indicating that a lack of association 
between SERT and the APP products is not from SERT not being present. It appears that some 
association is present between an APP metabolite and SERT that is likely the 72 kDa variant, but 
as with HEK293, no binding has occurred between Aβ and SERT, as can be seen in the final panel. 
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Figure 3.10: Fluoxetine does not prevent Aβ transport to the culture media in HEK293 
cells. 
After cells were transfected and treated in the same way described in Figure 15, IPs and urea WBs 
were utilized to isolate Aβ fragments containing amino acids 1-17 on the N-terminal by probing 
with 6E10. Aβ is undetectable within the soluble fraction of the cell and at least faintly evident 
within the corresponding culture media. Membrane of the cell soluble fraction was probed with 
1:500 6E10 in 5% BSA in 1xTBST and the media membrane with 1:1000 6E10 in 5% BSA in 
1xTBST. 
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Figure 3.11: Fluoxetine does not prevent Aβ transport to the culture media in HT22 cells. 
HT22 cells were transfected and treated as described in Figure 15. Unlike HEK293 cells, Aβ is 
unable to be detected within either set of samples, indicating that there are either issues with the 
detection method or this cell line was unable to produce the Aβ peptide. IPs and urea WBs pulled 
out Aβ fragments containing amino acids 1-17 on the N-terminal when probed with 1:500 6E10 
in 5% BSA in 1xTBST. 
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Figure 3.12: No interaction was observed between APP metabolites and SERT in HEK293 
cells. 
A sequential IP allowed sAPPα, C99, and C83 to be pulled out of the IP sample, before then 
isolating Aβ. After WBs using 7.5% gels, these samples were probed with anti-SERT, to search 
for any physical interaction between the APP metabolites and SERT. The image above also shows 
the initial SERT levels within the cells. Although SERT is present within all samples, any 
interaction between the four metabolites of APP and SERT cannot be observed. The membranes 
were probed twice with 1:500 anti-SERT in 5% BSA in 1xTBST. 
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Figure 3.13: No interaction was observed between APP metabolites and SERT in HT22 
cells. 
The same procedure described for Figure 18 was used in HT22 cells. The image above shows 
whether SERT interacts with sAPPα, C99, or C83; if SERT is physically connected to Aβ; and the 
SERT levels within the HT22 cell samples. No association can be seen between the four 
metabolites of APP and SERT in the HT22 samples although SERT is able to be detected within 
the cell lysate. The strong band on the bottom panel is from IgG. The membranes were probed 
twice with 1:500 anti-SERT in 5%BSA in 1xTBST. 
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4 Discussion 
4.1 Fluoxetine and nor-Fluoxetine promote intracellular Aβ peptide accumulation in C. 
elegans. 
The premise of this work was to experimentally investigate a possible molecular 
mechanism explaining how SSRIs exacerbate Aβ toxicity, a theory that comes from clinical studies 
showing a correlation between specific early-life depression treatments and late-life AD. The 
finding by Kessing and colleagues that there is an association between the type of antidepressant 
treatment and the risk for AD development120 implicates specifically SSRIs, but not other classes 
of antidepressant drugs, including other uptake inhibitors. C. elegans strains that ectopically 
expressed Aβ peptides in the body wall muscle and behaviour assays that quantify movement 
dysfunction associated with Aβ accumulation were used to observe the impact of Fluoxetine and 
nor-Fluoxetine. In addition, this organism was used to study components of the serotonin signaling 
pathway within a whole animal. Though the first assay used (testing paralysis on agar plates) 
suggested that SSRIs had no significant impact on Aβ-associated paralysis, these results could be 
the result of limitations of the technique and biased phenotypic scoring. When the experiments 
were repeated using a more quantitative readout phenotype (thrashing assay), it was observed that 
the SSRIs induced an exacerbated reduction in thrashing behaviour. This effect was associated 
with the production of Aβ1-42, but not Aβ3-42. These results confirmed a functional link between 
the mode of action of SSRIs and Aβ accumulation; however, this association is indirect as the 
change in Aβ accumulation inside the muscle cells has not been checked yet. It will be important 
to determine if a significant increase in Aβ1-42 can be detected using WBs in Fluoxetine and nor-
Fluoxetine treated animals compared to vehicle treated worms.  
 
4.2 SERT/MOD-5 link serotonergic and Aβ pathways in the synapsis/neuromuscular 
junction to influence monoamine turnover and Aβ processing in worms. 
Considering the conservation of Fluoxetine specificity to serotonin transporters, MOD-5 
was an obvious candidate in modulating the effect of SSRIs. As a membrane transporter that has 
been shown to bind other neurotoxic ligands163, MOD-5 could represent an export channel for Aβ 
peptides. Although the roles of extracellular and intracellular Aβ in the pathology of AD is still 
controversial, the removal of increasing loads of soluble intracellular Aβ peptides may prevent the 
formation of toxic plaques. In the artificial context of a transgenic model studied here, preventing 
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the clearance of Aβ leads to increasing accumulation of Aβ peptides in muscle tissue, evidenced 
by a systemic reduction in thrashing and, ultimately, paralysis of the whole organism. 
This work is not the first to suggest that there is a link between Aβ accumulation in C. 
elegans and serotonin signalling. Using a similar experimental approach, Wu et al. showed that 
the extract (EGb 761) from Ginkgo biloba can inhibit both Aβ oligomerization in neurons and 
hypersensitivity to exogenous serotonin, suggesting a shared regulation179. Interestingly, the 
authors noticed that Aβ expressing lines with normal MOD-5 function were more sensitive to 
exogenous serotonin, a hallmark of mod-5 mutants. This effect is completely suppressed by pre-
treatment with the G. biloba extract, indicating that Aβ oligomerization in the neuron correlates 
with reduced import of serotonin from the synapsis. One interpretation of this finding is that Aβ 
peptides may compete with serotonin for binding to MOD-5 in the membrane of neurons, resulting 
in a diminished import of serotonin in higher intracellular Aβ load situations leading to longer 
residence of serotonin in the synaptic cleft and higher sensitivity for this active monoamine. 
Though biochemical proof of Aβ binding to SERT/MOD-5 is not yet available, evidence from C. 
elegans strongly suggest that MOD-5 represent a shared notch between the serotonin signalling 
branch and the Aβ clearance pathway. To further explore this network, it would be interesting to 
revisit these findings to test whether inhibition of MOD-5 with SSRI treatment can interfere with 
EGb 761-mediated suppression of Aβ oligomerization and deposition in neurons. 
 
4.3 Lack of evidence of SERT-dependent Aβ export from mammalian cells.  
Alternatively, both the HEK293 and HT22 cell lines did not appear to be affected by SSRI 
use. It was hypothesized that Fluoxetine would block SERT and cause Aβ to remain within the 
cell, where those treated with a vehicle would allow Aβ to be transported to the media. The lysates 
were tested and confirmed that the transfection was effective (Figure 15), thus the later 
experiments (determining the location of Aβ and whether it colocalizes with SERT) being 
unsuccessful was not because the cells were not expressing APP, nor that they do not express 
SERT as this was also confirmed in Figure 14 and in the first panels of Figures 18 and 19. It was 
hypothesized that with SSRI treatment, Aβ would bind to SERT. Sequential IPs were used to 
immunodeplete C99, C83, and sAPPα into one sample and Aβ into another, then were probed for 
SERT after WBs were ran. Following the hypothesis, if the APP metabolites associated with 
SERT, this should be detected when probing for the transporter. Although all samples did have 
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detectable levels of SERT, the HEK293 cells did not show any banding after the SERT probe. This 
was unsurprising as it was shown in Figure 16 that the HEK293 cells did not have detectable levels 
of Aβ within the cells but was observed within the media. This helps confirm that no association 
between Aβ and SERT occurred within these samples. The HT22 cells also had detectable SERT 
levels within the cell lysate samples but showed no association between SERT and Aβ. HT22 may 
not have been capable of producing Aβ, as only larger APP metabolites around 15 kDa appear to 
be present (Figure 17) and is reflected by Figure 19 where a faint band is present around 55 kDa 
after the C-TERM IP. As the data displayed in Figures 16 and 17 did not agree with the hypothesis, 
and no difference is evident between the vehicle and the two treatment concentrations of 
Fluoxetine, it appears that the cell lines chosen may not have been proper models or that the 
detection method used was not sensitive enough to perceive any differences. This is discussed 
further in Section 4.4.  
 
4.4 Limitations of the worm and cell culture models 
 There are some limitations of the research described above. Firstly, the worm model used 
to study the effects of SSRIs on the accumulation of Aβ cannot be directly compared to the 
aggregation seen in human brains. Expression of Aβ occurs in body muscle cells in C. elegans, 
therefore, not directly affecting their neurons. Serotonin is known to have a multitude of roles in 
the human body, including vasoconstriction and coagulation, to name a few180, and is taken up by 
many different tissues, such as smooth muscle, brain, spleen, liver, lungs, and gut180. The specific 
role of serotonin on body muscle cells and if MOD-5 is present in these cells is not well 
documented. However, regulation of pharyngeal pumping in worms is controlled by serotonin181, 
indicating that it is possible for muscle cells within these nematodes to be regulated by this 
monoamine. It is clear in the thrashing experiments completed in this study that Fluoxetine and 
nor-Fluoxetine cause a significant effect in this worm model, but the precise action is unknown. 
The neuromuscular junction in C. elegans differs from vertebrates because the muscle cells extend 
axons towards the motor neurons and form synapses182; this location is likely where the SSRIs are 
acting to produce the effects described above. It is not clear whether the drugs used are acting on 
the muscle cell itself, producing the reduction in body bends, or directly on Aβ. As exogenous 
serotonin has been found to induce a number of behaviours in C. elegans, including slowed 
locomotion181, it could be argued that the SSRIs are increasing serotonin levels within the worm, 
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resulting in the reduced thrashing. However, the results displayed in Figure 12 dispute this idea. 
CEC218 worms express human Aβ1-42 and do not produce serotonin (tph-1), but still show the 
reduced levels of thrashing that are very similar to those observed in GMC101 worms, which can 
synthesize serotonin. It would follow that this change in serotonin availability or location caused 
by SSRIs in Aβ1-42-expressing (GMC101) worms cannot be responsible for the reduced thrashing 
phenotype if no difference is seen in worms that cannot produce serotonin. This does not quell all 
other arguments that could be made about there being off-target effects causing the phenotype 
observed, however, whether these effects are the result of an increase in Aβ could be easily tested. 
Once the detection method for Aβ has been optimized, this could be verified by determining if the 
amount of Aβ within the worms is increased when treated with an SSRI, compared to the vehicle 
by lysing the worms and testing with a urea/SDS-PAGE gel and 6E10 primary antibody probing.  
Another limitation of the worm model is that it has a human protein being produced within 
a non-human organism. The assumption used here is that the cellular environments within the 
worm muscle cells and the human neurons (these proteins are typically found in) are the same and 
allow for similar pathways to be present. If this assumption is incorrect, and the worms do not have 
the machinery to clear and metabolize this peptide, that would indicate that what we are seeing is 
not actually caused by SSRIs influencing Aβ. However, previous work has been done showing 
that C. elegans does have gene analogues to those present in humans, supporting the use of this 
model. These include mitoferrin-1, the mitochondrial solute carrier which, when knocked-down, 
reduces paralysis rate in GMC101 worms183; the presenilin homolog, sel-12184; and α-secretase, 
both of which can cleave human APP185. 
 In addition, the amount of Fluoxetine or nor-Fluoxetine consumed by the worms is 
currently unknown. Although the plates are seeded with a specific concentration of the SSRIs, the 
worms are not going to have an internal concentration of either compound the same as that on the 
plates because of the cuticle and the internal amount is likely variable from worm to worm. The 
treatment is determined by the amount of E. coli lawn that is eaten; this variation may be a factor 
attributing to the range in thrashing seen across the worms. Mass spectrometry could allow the 
detection of the compounds after the worm has consumed them. As well, this may be used to detect 
specific differences in the chemical structures of compounds within the lysed worm solution, 
which could be used to determine if the worm can metabolize the drugs.  
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 The mammalian cell culture also had some limitations; this model does not take a whole 
organism into account. Although cell culture does allow the effects of Fluoxetine to be tested in 
mammalian cells, this only shows effects at a cellular level and likely differs from what may 
happen in a whole organism. A rodent model could be an appropriate next step to determine if 
treatment with SSRIs increases the organism’s risk for AD. 
Following the work discussed, there are still a multitude of questions that need to be 
answered. Firstly, once the detection method is optimized, both Fluoxetine and nor-Fluoxetine 
need to be used to treat APP-transfected HEK293 and HT22 cells to determine if Fluoxetine and 
its metabolite produce similar effects, as seen in C. elegans. As well, multiple antidepressant drugs 
need to be tested in cell culture to display whether all SSRIs have similar actions regarding Aβ 
accumulation and localization and if other classes differ in effect. These objectives could be 
achieved similarly to the previous cell culture procedures, with the cells being transfected to 
express human APP, treated, IPs performed, and tested with urea/SDS-PAGE.  
In this study only two concentrations of Fluoxetine were used for the cell culture 
treatments. After further tests are done to accept or reject the original hypothesis, a greater range 
of drug concentrations could show if the switch from seeing Aβ in the media to finding it in the 
cell occurs at a specific concentration or if the amount seen in each location is dose-dependent and 
gradually changes. If any interesting results were found when using other compounds, this 
technique could be employed as well. 
 Although C. elegans and cell culture are useful models for neurodegeneration and to screen 
the effects of antidepressant drugs without the extra interfering factors that a larger, more complex 
organism can give, these are only predictive models of this disorder. It would be interesting to 
study the effects of antidepressant drug use on AD development in a mouse or rat model, as these 
are evolutionarily closer to humans. How earlier use of antidepressant drugs compares to use later 
in life could be studied, as well as, if longer treatment shows a greater increased risk of late-life 
AD. At the end of the study, after being sacrificed, the brains of the animals could be tested for 
their Aβ burden. In addition, it has been reported that treatment with SSRIs at doses below the 
lowest typical treatment dose might be able to treat depression without increasing risk for AD186. 
A smaller dose could be tested to determine its efficacy. This could be an ideal treatment, if 
successful, as it could still prevent the uptake of serotonin, increasing its availability, while not 
saturating the transporter, allowing Aβ to leave the neuron. To be able to make confident 
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hypotheses about what the chronic effects of antidepressant drugs are in the human body, a 
mammalian model will need to be tested first.  
Finally, there may be more than one binding site for SSRIs on SERT; this theory would 
explain why other uptake inhibitors do not display the same risk factor for AD as SSRIs. SSRIs 
may be binding to a site causing a conformational change within the transporter. This change could 
prevent Aβ from associating with the second binding site on SERT and halt its removal from the 
cell. Other drugs that display no increased risk for AD, such as TCAs120, may bind to the second 
transporter binding site allowing the movement of Aβ to continue. This is supported by the finding 
that men and women have greater efficacy with different classes of antidepressant drugs and 
suggests that there may be other structural differences between male and female SERT. 
Determining whether two binding sites are present on the transporter, and if any differences can 
be detected between the sexes, could allow for more selective antidepressant drugs to be 
developed. 
 
4.5 Clinical implications of the effects of SSRI usage on Aβ accumulation  
 Antidepressant drugs are one of the most commonly prescribed types of medications, with 
SSRIs continuing to increase in use187, and has risen for almost four decades188. As well, other off-
label uses of SSRIs have been found, increasing the number of people utilizing this type of drug. 
Unlike other antidepressant drug options, such as MAOIs, SSRIs appear to be a safer and more 
convenient choice when selecting a compound to prescribe. Although other classes have more 
acute side effects to consider and monitor, SSRIs may have more serious chronic side effects if 
their use is continued for a longer duration. If these compounds can increase a person’s risk for 
AD, they should not be the first option chosen when looking for a depression treatment without 
receiving more information from the patient. The family history and other AD risk factors, such 
as presence of affective disorders, need to be considered when prescribing an antidepressant drug. 
A meta-analysis by Moraros et al. found that individuals with AD are more likely to have been 
treated with antidepressant drugs, and that this association is more evident in people treated before 
the age of 65161. This effect could be the result of many factors. Rate of metabolism is different 
across age ranges causing those treated with antidepressant drugs in early adulthood to metabolize 
the drugs faster, producing more of the metabolites. The work described above in C. elegans 
suggests that nor-Fluoxetine has very similar effects on the accumulation of Aβ to that seen for 
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Fluoxetine. As nor-Fluoxetine has a longer half-life, and seemingly has the same effects as the 
parent compound, this could cause the heightened effects found in younger cohorts. As well, 
younger adults have a greater chance for an extended duration of treatment if a disorder presents 
at an earlier age compared to an elderly patient. This is not to say that SSRIs have no benefit, but 
that more consideration should be taken in the treatment process. As already stated, other types of 
antidepressant drugs do not show the same risk for AD as has been associated with SSRIs120. 
 Another factor to consider is that the increased risk in AD development may not uniformly 
affect the population. With a theorised difference in efficacy between TCAs and SSRIs in males 
and females130–133, women may be more likely to be prescribed an SSRI over other antidepressant 
drug options because of its higher success rate. TCAs were not found to cause an increased risk 
for AD development, so its use in males would likely not be an additional risk factor. Depression 
is more commonly diagnosed in women, thus if SSRIs are thought to have minimal side effects 
and have greater success in females, their use could be increasing the risk of AD in these women.  
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6 Appendices 
Appendix A: Western Blot Constituents 
Table A.1: Urea/SDS-PAGE Recipe 
 
Separation Buffer: 9.7 g Tris + 1.1 mL H
2
SO4 in 50 mL ddH2O for a final concentration of 1.6 M 
Tris + 0.4 M H
2
SO4 
Stacking Buffer: 8.4 g Bistris + 555 μL H
2
SO4 in 50 mL ddH2O for a final concentration of 0.8 M 
Bistris + 0.2 M H
2
SO4 
Comb Buffer: 7.5 g Bistris + 2.6 g Bicine in ddH
2
O in 50 mL ddH
2
O for a final concentration of 
0.72 M Bistris + 0.32 M Bicine 
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Table A.2: Western Blot Ingredients 
 
Buffer A: 18.45 g Tris Base + 77.0 g Tric HCl + 2.0 g SDS diluted to 500 mL dH2O to a final pH 
of 8.8 
Buffer C: 30.0 g Tric HCl + 2.0 g SDS diluted to 500 mL dH2O to a final pH of 6.8  
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Appendix B: Calculated Statistical Values 
Table B.1: Paralysis Results  
Strain Treatment Vehicle χ2 Value P Value Sample Size 
CL2120 Fluoxetine Live 2.842 0.241 218 
Dead 2.069 0.355 219 
GMC101 Live 1.241 0.538 228 
Dead 0.687 0.709 224 
CL2120 nor-Fluoxetine Live 1.807 0.405 231 
Dead 0.488 0.783 231 
GMC101 Live 1.824 0.402 233 
Dead 0.135 0.935 217 
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Table B.2: Thrashing results from CL2122 worms treated with Fluoxetine 
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Table B.3: Thrashing results from CL2120 worms treated with Fluoxetine 
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Table B.4: Thrashing results from GMC101 worms treated with Fluoxetine 
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Table B.5: Thrashing results from CL2122 worms treated with nor-Fluoxetine 
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Table B.6: Thrashing results from CL2120 worms treated with nor-Fluoxetine 
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Table B.7: Thrashing results from GMC101 worms treated with nor-Fluoxetine 
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Table B.8: Thrashing results from CEC215 strain comparison 
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Table B.9: Thrashing results from CEC218 strain comparison 
 
 
 
 
 
